US20090326077A1 - Polyisobutylene urethane, urea and urethane/urea copolymers and medical devices containing the same - Google Patents
Polyisobutylene urethane, urea and urethane/urea copolymers and medical devices containing the same Download PDFInfo
- Publication number
- US20090326077A1 US20090326077A1 US12/492,440 US49244009A US2009326077A1 US 20090326077 A1 US20090326077 A1 US 20090326077A1 US 49244009 A US49244009 A US 49244009A US 2009326077 A1 US2009326077 A1 US 2009326077A1
- Authority
- US
- United States
- Prior art keywords
- segment
- copolymer
- diol
- polyisobutylene
- polymeric
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 C*OC(=O)OC Chemical compound C*OC(=O)OC 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
- C08G18/40—High-molecular-weight compounds
- C08G18/62—Polymers of compounds having carbon-to-carbon double bonds
- C08G18/6204—Polymers of olefins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/18—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/06—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/08—Processes
- C08G18/10—Prepolymer processes involving reaction of isocyanates or isothiocyanates with compounds having active hydrogen in a first reaction step
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/08—Processes
- C08G18/10—Prepolymer processes involving reaction of isocyanates or isothiocyanates with compounds having active hydrogen in a first reaction step
- C08G18/12—Prepolymer processes involving reaction of isocyanates or isothiocyanates with compounds having active hydrogen in a first reaction step using two or more compounds having active hydrogen in the first polymerisation step
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
- C08G18/40—High-molecular-weight compounds
- C08G18/4009—Two or more macromolecular compounds not provided for in one single group of groups C08G18/42 - C08G18/64
- C08G18/4063—Mixtures of compounds of group C08G18/62 with other macromolecular compounds
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
- C08G18/40—High-molecular-weight compounds
- C08G18/48—Polyethers
- C08G18/4854—Polyethers containing oxyalkylene groups having four carbon atoms in the alkylene group
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
- C08G18/40—High-molecular-weight compounds
- C08G18/48—Polyethers
- C08G18/4858—Polyethers containing oxyalkylene groups having more than four carbon atoms in the alkylene group
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
- C08G18/65—Low-molecular-weight compounds having active hydrogen with high-molecular-weight compounds having active hydrogen
- C08G18/6505—Low-molecular-weight compounds having active hydrogen with high-molecular-weight compounds having active hydrogen the low-molecular compounds being compounds of group C08G18/32 or polyamines of C08G18/38
- C08G18/6511—Low-molecular-weight compounds having active hydrogen with high-molecular-weight compounds having active hydrogen the low-molecular compounds being compounds of group C08G18/32 or polyamines of C08G18/38 compounds of group C08G18/3203
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/70—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the isocyanates or isothiocyanates used
- C08G18/72—Polyisocyanates or polyisothiocyanates
- C08G18/74—Polyisocyanates or polyisothiocyanates cyclic
- C08G18/76—Polyisocyanates or polyisothiocyanates cyclic aromatic
- C08G18/7657—Polyisocyanates or polyisothiocyanates cyclic aromatic containing two or more aromatic rings
Definitions
- the present invention relates to urethane, urea and urethane/urea copolymers and to medical devices containing the same.
- polymeric materials in medical devices for implantation or insertion into the body of a patient is common in the practice of modern medicine.
- polymeric materials such as silicone rubber, polyurethane, and fluoropolymers, for instance, polytetrafluoroethylene (PTFE), expanded PTFE (ePTFE) and ethylene tetrafluoroethylene (ETFE), are used as coating materials/insulation for medical leads, providing mechanical protection, electrical insulation, or both.
- PTFE polytetrafluoroethylene
- ePTFE expanded PTFE
- ETFE ethylene tetrafluoroethylene
- drug eluting stents are known which have polymeric coatings over the stent to release a drug to counteract the effects of in-stent restenosis.
- drug eluting coronary stents include commercially available stents from Boston Scientific Corp. (TAXUS, PROMUS), Johnson & Johnson (CYPHER), and others. See S. V. Ranade et al., Acta Biomater. 2005 January; 1 (1): 137-44 and R. Virmani et al., Circulation 2004 Feb. 17, 109 (6) 701-5.
- polymeric materials have been used in such polymeric coatings including, for example, homopolymers such as poly(n-butyl methacrylate) and copolymers such as poly(ethylene-co-vinyl acetate), poly(vinylidene fluoride-co-hexafluoropropylene), and poly(isobutylene-co-styrene), for example, poly(styrene-b-isobutylene-b-styrene) triblock copolymers (SIBS), which are described, for instance, in U.S. Pat. No. 6,545,097 to Pinchuk et al.
- SIBS poly(styrene-b-isobutylene-b-styrene) triblock copolymers
- SIBS triblock copolymers have a soft, elastomeric low glass transition temperature (Tg) midblock and hard elevated Tg endblocks. Consequently, SIBS copolymers are thermoplastic elastomers, in other words, elastomeric (i.e., reversibly deformable) polymers that form physical crosslinks which can be reversed by melting the polymer (or, in the case of SIBS, by dissolving the polymer in a suitable solvent). SIBS is also highly biocompatible.
- the present invention pertains to polyisobutylene urethane copolymers, to polyisobutylene urea copolymers, to polyisobutylene urethane/urea copolymers, to methods of making such copolymers and to medical devices that contain such polymers.
- polyurethanes, polyureas and polyurethane/polyureas which comprise a polyisobutylene segment, an additional polymeric segment that is not a polyisobutylene segment, and a segment comprising a residue of a diisocyanate.
- polyurethanes, polyureas and polyurethane/polyureas comprise a polyisobutylene segment and end groups that comprise alkyl-, alkenyl- or alkynyl-chain-containing end groups.
- polymers are molecules containing multiple copies (e.g., from 5 to 10 to 25 to 50 to 100 to 250 to 500 to 1000 or more copies) of one or more constitutional units, commonly referred to as monomers.
- monomers may refer to free monomers and to those that have been incorporated into polymers, with the distinction being clear from the context in which the term is used.
- Polymers may take on a number of configurations, which may be selected, for example, from linear, cyclic and branched configurations, among others.
- Branched configurations include star-shaped configurations (e.g., configurations in which three or more chains emanate from a single branch point), comb configurations (e.g., configurations having a main chain and a plurality of side chains, also referred to as “graft” configurations), dendritic configurations (e.g., arborescent and hyperbranched polymers), and so forth.
- homopolymers are polymers that contain multiple copies of a single constitutional unit (i.e., monomer).
- Copymers are polymers that contain multiple copies of at least two dissimilar constitutional units.
- a “polymeric segment” or “segment” is a portion of a polymer. Segments can be unbranched or branched. Segments can contain a single type of constitutional unit (also referred to herein as “homopolymeric segments”) or multiple types of constitutional units (also referred to herein as “copolymeric segments”) which may be present, for example, in a random, statistical, gradient, or periodic (e.g., alternating) distribution.
- a soft segment is one that displays a Tg that is below body temperature, more typically from 35° C. to 20° C. to 0° C. to ⁇ 25° C. to ⁇ 50° C. or below.
- a hard segment is one that displays a Tg that is above body temperature, more typically from 40° C. to 50° C. to 75° C. to 100° C. or above.
- Tg can be measured by differential scanning calorimetry (DSC), dynamic mechanical analysis (DMA) and thermomechanical analysis (TMA).
- Polyurethanes are a family of copolymers that are synthesized from polyfunctional isocyanates (e.g., diisocyanates, including both aliphatic and aromatic diisocyanates) and polyols (e.g., macroglycols). Commonly employed macroglycols include polyester diols, polyether diols and polycarbonate diols. Typically, aliphatic or aromatic diols or diamines are also employed as chain extenders, for example, to impart improved physical properties to the polyurethane. Where diamines are employed as chain extenders, urea linkages are formed and the resulting polymers may be referred to as polyurethane/polyureas
- Polyureas are a family of copolymers that are synthesized from polyfunctional isocyanates and polyamines, for example, diamines such as polyester diamines, polyether diamines, polysiloxane diamines, polyhydrocarbon diamines and polycarbonate diamines.
- diamines such as polyester diamines, polyether diamines, polysiloxane diamines, polyhydrocarbon diamines and polycarbonate diamines.
- aliphatic or aromatic diols or diamines may be employed as chain extenders.
- Urethane, urea and urethane/urea copolymers in accordance with the invention typically comprise one or more polyisobutylene segments.
- polyisobutylene urethane, urea and urethane/urea copolymers which contain (a) one or more polyisobutylene segments, (b) one or more additional polymeric segments (other than polyisobutylene segments), and (c) one or more segments that contains one or more diisocyanate residues and, optionally, one or more chain extender residues.
- additional polymeric segments include soft polymeric segments such as polyether segments, fluoropolymer segments including fluorinated polyether segments, polyester segments, poly(acrylate) segments, poly(methacrylate) segments, polysiloxane segments and polycarbonate segments.
- soft polyether segments include linear, branched and cyclic homopoly(alkylene oxide) and copoly(alkylene oxide) segments, including homopolymeric and copolymeric segments formed from one or more of the following, among others: methylene oxide, dimethylene oxide (ethylene oxide), trimethylene oxide, propylene oxide, and tetramethylene oxide.
- soft fluoropolymer segments include perfluoroacrylate segments and fluorinated polyether segments, for example, linear, branched and cyclic homopoly(fluorinated alkylene oxide) and copoly(fluorinated alkylene oxide) segments, including homopolymeric and copolymeric segments formed from one or more of the following, among others: perfluoromethylene oxide, perfluorodimethylene oxide (perfluoroethylene oxide), perfluorotrimethylene oxide and perfluoropropylene oxide.
- soft polyester segments include linear, branched and cyclic homopolymeric and copolymeric segments formed from one or more of the following, among others: alkyleneadipates including ethyleneadipate, propyleneadipate, tetramethyleneadipate, and hexamethyleneadipate.
- soft poly(acrylate) segments include linear, branched and cyclic homopoly(acrylate) and copoly(acrylate) segments, including homopolymeric and copolymeric segments formed from one or more of the following, among others: alkyl acrylates such as methyl acrylate, ethyl acrylate, propyl acrylate, isopropyl acrylate, butyl acrylate, sec-butyl acrylate, isobutyl acrylate, 2-ethylhexyl acrylate and dodecyl acrylate
- alkyl acrylates such as methyl acrylate, ethyl acrylate, propyl acrylate, isopropyl acrylate, butyl acrylate, sec-butyl acrylate, isobutyl acrylate, 2-ethylhexyl acrylate and dodecyl acrylate
- soft poly(methacrylate) segments include linear, branched and cyclic homopoly(methacrylate) and copoly(methacrylate) segments, including homopolymeric and copolymeric segments formed from one or more of the following, among others: alkyl methacrylates such as hexyl methacrylate, 2-ethylhexyl methacrylate, octyl methacrylate, dodecyl methacrylate and octadecyl methacrylate.
- alkyl methacrylates such as hexyl methacrylate, 2-ethylhexyl methacrylate, octyl methacrylate, dodecyl methacrylate and octadecyl methacrylate.
- soft polysiloxane segments include linear, branched and cyclic homopolysiloxane and copolysiloxane segments, including homopolymeric and copolymeric segments formed from one or more of the following, among others: dimethyl siloxane, diethyl siloxane, and methylethyl siloxane.
- soft polycarbonate segments include those comprising one or more types of carbonate units,
- R may be selected from linear, branched and cyclic alkyl groups. Specific examples include homopolymeric and copolymeric segments formed from one or more of the following monomers, among others: ethylene carbonate, propylene carbonate, and hexamethylene carbonate.
- additional polymeric segments also include hard polymeric segments such as poly(vinyl aromatic) segments, poly(alkyl acrylate) and poly(alkyl methacrylate) segments.
- hard poly(vinyl aromatic) segments include linear, branched and cyclic homopoly(vinyl aromatic) and copoly(vinyl aromatic) segments, including homopolymeric and copolymeric segments formed from one or more of the following vinyl aromatic monomers, among others: styrene, 2-vinyl naphthalene, alpha-methyl styrene, p-methoxystyrene, p-acetoxystyrene, 2-methylstyrene, 3-methylstyrene and 4-methylstyrene.
- vinyl aromatic monomers among others: styrene, 2-vinyl naphthalene, alpha-methyl styrene, p-methoxystyrene, p-acetoxystyrene, 2-methylstyrene, 3-methylstyrene and 4-methylstyrene.
- hard poly(acrylate) segments include linear, branched and cyclic homopoly(alkyl acrylate) and copoly(alkyl acrylate) segments, including homopolymeric and copolymeric segments formed from one or more of the following acrylate monomers, among others: tert-butyl acrylate, hexyl acrylate and isobornyl acrylate.
- hard poly(alkyl methacrylate) segments include linear, branched and cyclic homopoly(alkyl methacrylate) and copoly(alkyl methacrylate) segments, including homopolymeric and copolymeric segments formed from one or more of the following alkyl methacrylate monomers, among others: methyl methacrylate, ethyl methacrylate, isopropyl methacrylate, isobutyl methacrylate, t-butyl methacrylate, and cyclohexyl methacrylate.
- polymeric segments described herein can vary widely in molecular weight, but typically are composed of between 2 and 100 repeat units (monomer units).
- polyurethanes can be incorporated into the polyurethanes, polyureas and polyurethane/polyureas of the invention by providing them in the form of polyols (e.g., diols, triols, etc.) and polyamines (e.g., diamines, triamines, etc.).
- polyols e.g., diols, triols, etc.
- polyamines e.g., diamines, triamines, etc.
- polyisobutylene polyols include linear polyisobutylene diols and branched (three-arm) polyisobutylene triols. See, e.g., J. P. Kennedy et al., “Designed Polymers by Carbocationic Macromolecular Engineering: Theory and Practice,” Hanser Publishers 1991, pp. 191-193, Joseph P. Kennedy, Journal of Elastomers and Plastics 1985 17: 82-88, and the references cited therein.
- polystyrene-co-isobutylene diols include poly(styrene-b-isobutylene-b-styrene) diols which may be formed, for example, using methods analogous to those described in the preceding Kennedy references.
- polyether polyols include polytetramethylene oxide diols, which are available from various sources including Signa-Aldrich Co., Saint Louis, Mo., USA and E. I. duPont de Nemours and Co., Wilmington, Del., USA.
- polysiloxane polyols examples include polydimethylsiloxane diols, available from various sources including Dow Corning Corp., Midland Mich., USA, Chisso Corp., Tokyo, Japan.
- polycarbonate polyols examples include polyhexamethylene carbonate diols such as those available from Sigma-Aldrich Co.
- polyfluoroalkylene oxide diols examples include ZDOLTX, Ausimont, Bussi, Italy, a copolyperfluoroalkylene oxide diol containing a random distribution of —CF 2 CF 2 O— and —CF 2 O— units, end-capped by ethoxylated units, i.e., H(OCH 2 CH 2 ) n OCH 2 CF 2 O(CF 2 CF 2 O) p (CF 2 O) q CF 2 CH 2 —O—(CH 2 CH 2 O) n H, where n, p and q are integers.
- Polystyrene diol ( ⁇ , ⁇ -dihydroxy-terminated polystyrene) of varying molecular weight is available from Polymer Source, Inc., Montreal, Canada. Polystyrene diols and three-arm triols may be formed, for example, using procedures analogous to those described in M. WeiBmüller et al., “Preparation and end-linking of hydroxyl-terminated polystyrene star macromolecules,” Macromolecular Chemistry and Physics 200 (3), 1999, 541-551.
- polyols e.g., diols, triols, etc.
- block copolymer polyols include poly(tetramethylene oxide-b-isobutylene) diol, poly(tetramethylene oxide-b-isobutylene-b-alkylene oxide) diol, poly(dimethyl siloxane-b-isobutylene) diol, poly(dimethyl siloxane-b-isobutylene-b-dimethyl siloxane) diol, poly(hexamethylene carbonate-b-isobutylene) diol, poly(hexamethylene carbonate-b-isobutylene-b-hexamethylene carbonate) diol, poly(methyl methacrylate-b-isobutylene) diol, poly(methyl methacrylate-b-isobutylene-b-methyl methacrylate) diol,
- polyisobutylene urethane, urea and urethane/urea copolymers in accordance with the invention typically contain one or more segments that contain one or more diisocyanate residues and, optionally, one or more chain extender residues.
- Diisocyanates for use in forming the urethane, urea and urethane/urea copolymers of the invention include aromatic and non-aromatic (e.g., aliphatic) diisocyanates.
- Aromatic diisocyanates may be selected from suitable members of the following, among others: 4,4′-methylenediphenyl diisocyanate (MDI), 2,4- and/or 2,6-toluene diisocyanate (TDI), 1,5-naphthalene diisocyanate (NDI), para-phenylene diisocyanate, 3,3′-tolidene-4,4′-diisocyanate and 3,3′-dimethyl-diphenylmethane-4,4′-diisocyanate.
- MDI 4,4′-methylenediphenyl diisocyanate
- TDI 2,4- and/or 2,6-toluene diisocyanate
- NDI 1,5-naphthalene diis
- Non-aromatic diisocyanates may be selected from suitable members of the following, among others: 1,6-hexamethylene diisocyanate (HDI), 4,4′-dicyclohexylmethane diisocyanate, 3-isocyanatomethyl-3,5,5-trimethylcyclohexyl isocyanate (isophorone diisocyanate or IPDI), cyclohexyl diisocyanate, and 2,2,4-trimethyl-1,6-hexamethylene diisocyanate (TMDI).
- HDI 1,6-hexamethylene diisocyanate
- IPDI isophorone diisocyanate
- TMDI 2,2,4-trimethyl-1,6-hexamethylene diisocyanate
- Optional chain extenders are typically aliphatic or aromatic diols (in which case a urethane bond is formed upon reaction with an isocyanate group) or aliphatic or aromatic diamines (in which case a urea bond is formed upon reaction with an isocyanate group).
- Chain extenders may be selected from suitable members of the following, among others: alpha,omega-alkane diols such as ethylene glycol (1,2-ethane diol), 1,4-butanediol, 1,6-hexanediol, alpha,omega-alkane diamines, such as ethylene diamine, dibutylamine (1,4-butane diamine) and 1,6-hexanediamine, or 4,4′-methylene bis(2-chloroaniline).
- alpha,omega-alkane diols such as ethylene glycol (1,2-ethane diol), 1,4-butanediol, 1,6-hexanediol
- alpha,omega-alkane diamines such as ethylene diamine, dibutylamine (1,4-butane diamine) and 1,6-hexanediamine, or 4,4′-methylene bis(2-chloroaniline).
- Chain extenders may be also selected from suitable members of the following, among others: short chain diol polymers (e.g., alpha,omega-dihydroxy-terminated polymers having a molecular weight less than or equal to 1000) based on hard and soft polymeric segments (more typically soft polymeric segments) such as those described above, including short chain polyisobutylene diols, short chain polyether polyols such as polytetramethylene oxide diols, short chain polysiloxane diols such as polydimethylsiloxane diols, short chain polycarbonate diols such as polyhexamethylene carbonate diols, short chain poly(fluorinated ether) diols, short chain polyester diols, short chain polyacrylate diols, short chain polymethacrylate diols, and short chain poly(vinyl aromatic) diols.
- short chain diol polymers e.g., alpha,omega-di
- chain extenders can increase the hard segment length (or, stated another way, can increase the ratio of hard segment material to soft segment material in the urethane, urea or urethane/urea polymer), which can in turn result in a polymer with higher modulus, lower elongation at break and increased strength.
- polyisobutylene urethane, urea and urethane/urea copolymers which comprise (a) one or more polyisobutylene segments, (b) optionally, one or more additional segments other than polyisobutylene segments, (c) one or more diisocyanate residues, (d) optionally, one or more chain extender residues, and (e) end groups that comprise alkyl, alkenyl or alkynyl chains ranging from 1 to 18 carbons in length.
- such end groups may be selected from [—CH 2 ] n —CH 3 groups, [—CH 2 ] n —CF 3 groups, [—CH 2 ] n —C 6 H 5 groups (i.e., [—CH 2 ] n -ph) and combinations thereof, among others, where n ranges from 1 to 17 (e.g., 1 to 2 to 3 to 4 to 5 to 6 to 7 to 8 to 9 to 10 to 11 to 12 to 13 to 14 to 15 to 16 to 17).
- Polyisobutylene urethane, urea and urethane/urea copolymers in accordance with the invention may the synthesized, for example, in bulk or using a suitable solvent (e.g., one capable or dissolving the various species that participate in the polymerization reaction).
- a suitable solvent e.g., one capable or dissolving the various species that participate in the polymerization reaction.
- Various synthetic strategies may be employed to create polyisobutylene urethane, urea and urethane/urea polymers in accordance with the invention. These strategies typically involved the reaction of (a) one or more polyol (commonly diol) species and one or more polyisocyanate (commonly diisocyanate) species, (b) one or more polyamine (commonly diamine) species and one or more polyisocyanate species, or (c) one or more polyol species, one or more polyamine species and one or more polyisocyanate species. Reaction may be conducted, for example, in organic solvents, or using supercritical CO 2 as a solvent. Ionomers can be used for polymer precipitation.
- a one step method may be employed in which a first macrodiol (M1) (e.g., a block copolymer diol such as SIBS diol, etc.) and a diisocyante (DI) (e.g., MDI, TDI, etc.) are reacted in a single step. Molar ratio of diisocyanate relative to the first macrodiol is 1:1.
- a polyurethane having alternating macrodiol and diisocyante residues i.e., -[DI-M1-] n , where n is an integer, may be formed.
- a diol or diamine chain extender (e.g., 1,2-ethane diol, 1,4-butanediol, 1,6-hexanediol, etc.) is included in the reaction mixture, in which case the molar ratio of diisocyanate relative to the combination of the first macrodiol and the chain extender is 1:1.
- the ratio DI:M1:CE may equal 2:1:1, may equal 2:1.5:0.5, may equal 2:0.5:1.5, among many other possibilities.
- a polyurethane having the following structure may be formed -[DI-M1-DI-CE-] n .
- a two-step reaction is employed wherein the first macrodiol and diisocyante are reacted in a single step at a DI:M1 molar ratio of ⁇ 2:1 in order to form isocyanate-end-capped “prepolymers,” DI-M1-DI. Then, in a second step, a chain extender is added, along with additional diisocyanate, if required to maintain an overall molar ratio of diisocyanate relative to the combination of the first macrodiol and the chain extender of 1:1.
- a polyurethane having the following structure may be formed -[DI-M1-DI-CE-] n , although the M1 and CE residues may not be perfectly alternating as shown. Due to enhanced reaction control, polyurethanes made by the two-step method tend to have a more regular structure than corresponding polyurethanes made by the one step method.
- a one step method may be employed in which a first macrodiol (M1) (e.g., a polyisobutylene diol, a SIBS diol, etc.), a second macrodiol (M2) (e.g., a polyether diol, a fluoropolymer diol, a polysiloxane diol, a polycarbonate diol, a polyester diol, a polyacrylate diol, a polymethacrylate diol, a polystyrene diol, etc.) and a diisocyante (DI) (e.g., MDI, TDI, etc.) are reacted in a single step.
- M1 e.g., a polyisobutylene diol, a SIBS diol, etc.
- M2 e.g., a polyether diol, a fluoropolymer diol, a poly
- Molar ratio of diisocyanate relative to the first and second diols is 1:1.
- the ratio DI:M1:M2 may equal 2:1:1, may equal 2:1.5:0.5, may equal 2:0.5:1.5, among many other possibilities.
- a ratio of DI:M1:M2 equal to 2:1:1 is employed, a polyurethane having the following structure may be formed -[DI-M1-DI-M2-] n although the chains are unlikely to be perfectly alternating as shown.
- a chain extender is added to the reaction mixture, such that the molar ratio of diisocyanate relative to the first and second macrodiols and chain extender is 1:1.
- the ratio DI:M1:M2:CE may equal 4:1:1:2, may equal 2:0.67:0.33:1, may equal 2:0.33:0.67:1, or may equal 5:1:1:3, among many other possibilities.
- a ratio of DI:M1:M2:CE equal to 4:1:1:2 is employed, a polyurethane having the following structure may be formed -[DI-M1-DI-CE-DI-M2-DI-CE-] n , although the chains are unlikely to be perfectly alternating as shown.
- a two-step method is employed in which first and second macrodiols and diisocyante are reacted in a ratio of DI:M1:M2 of ⁇ 2:1:1 in a first step to form isocyanate capped first and second macrodiols, for example DI-M1-DI and DI-M2-DI.
- a chain extender is added which reacts with the isocyanate end caps of the macrodiols.
- the number of moles of hydroxyl or amine groups of the chain extender may exceed the number of moles of isocyanate end caps for the macrodiols, in which case additional diisocyante may be added in the second step as needed to maintain a suitable overall stoichiometry.
- the molar ratio of diisocyanate relative to the total of the first macrodiol, second macrodiol, and chain extender is typically 1:1, for example, DI:M1:M2:CE may equal 4:1:1:2, which may in theory yield an idealized polyurethane having the following repeat structure -[DI-M1-DI-CE-DI-M2-DI-CE-] n , although the chains are unlikely to be perfectly alternating as shown.
- the DI:M1:M2:CE ratio may equal 4:1.5:0.5:2 or may equal 5:1:1:3, among many other possibilities.
- three, four or more steps may be employed in which a first macrodiol and diisocyante are reacted in a first step to form isocyanate capped first macrodiol, typically in a DI:M1 ratio of ⁇ 2:1 such that isocyanate end caps are formed at each end of the first macrodiol (although other ratios are possible including a DI:M1 ratio of 1:1, which would yield an average of one isocyanate end caps per macrodiol).
- This step is followed by second step in which the second macrodiol is added such that it reacts with one or both isocyanate end caps of the isocyanate capped first macrodiol.
- this step may be used to create structures (among other statistical possibilities) such as M2-DI-M1-DI-M2 (for a DI:M1:M2 ratio of 2:1:2), M2-DI-M1-DI (for a DI:M1:M2 ratio of 2:1:1), or M1-DI-M2 (for a DI:M1:M2 ratio of 1:1:1).
- structures such as M2-DI-M1-DI-M2 (for a DI:M1:M2 ratio of 2:1:2), M2-DI-M1-DI (for a DI:M1:M2 ratio of 2:1:1), or M1-DI-M2 (for a DI:M1:M2 ratio of 1:1:1).
- a mixed macrodiol prepolymer such as one of those in the prior paragraph, among others (e.g., M2-DI-M1-DI-M2, M1-DI-M2-DI-M1, DI-M1-DI-M2, etc.) is reacted simultaneously with a diol or diamine chain extender and a diisocyanate, as needed to maintain stoichiometry.
- the chain extension process may be used to create idealized structures along the following lines, among others: -[DI-M2-DI-M1-DI-M2-DI-CE-] n , -[DI-M1-DI-M2-DI-M1-DI-CE-] n or -[DI-M1-DI-M2-DI-CE-] n , although it is again noted that the chains are not likely to be perfectly alternating as shown.
- a mixed macrodiol prepolymer is reacted with sufficient diisocyanate to form isocyanate end caps for the mixed macrodiol prepolymer (e.g., yielding DI-M2-DI-M1-DI-M2-DI, DI-M1-DI-M2-DI-M1-DI or DI-M1-DI-M2-DI, among other possibilities).
- This isocyanate-end-capped mixed macrodiol can then be reacted with a diol or diamine chain extender (and a diisocyanate, as needed to maintain stoichiometry).
- the isocyanate-end-capped mixed macrodiol can be reacted with an equimolar amount of a chain extender to yield idealized structures of the following formulae, among others: -[DI-M2-DI-M1-DI-M2-DI-CE-] n , -[DI-M1-DI-M2-DI-M1-DI-CE-] n or -[DI-M1-DI-M2-DI-CE-] n .
- urethane, urea and urethane/urea molecules having alkyl-, alkenyl- or alkynyl-chain-containing end groups such as [—CH 2 ] n —CH 3 or [—CH 2 ] n —CF 3 or [—CH 2 ] n —C 6 H 5 end groups, among many others.
- such polymers may be formed by reacting a urethane, urea or urethane/urea copolymer such as one of those described above with a molecule of the formula HO[—CH 2 ] n —CH 3 or of the formula
- implantable and insertable medical devices contain one or more polymeric regions containing one or more polyisobutylene urethane, urea or urethane/urea copolymers.
- a “polymeric region” is a region (e.g., an entire device, a device component, a device coating layer, etc.) that contains polymers, for example, from 50 wt % or less to 75 wt % to 90 wt % to 95 wt % to 97.5 wt % to 99 wt % or more polymers.
- implantable electrical stimulation systems including neurostimulation systems such as spinal cord stimulation (SCS) systems, deep brain stimulation (DBS) systems, peripheral nerve stimulation (PNS) systems, gastric nerve stimulation systems, cochlear implant systems, and retinal implant systems, among others, and cardiac systems including implantable pacemaker systems, implantable cardioverter-defibrillators (ICD's), and cardiac resynchronization and defibrillation (CRDT) devices, including polymeric components for leads including lead insulation, outer body insulation, and components for the foregoing implantable electrical stimulation systems, stents (including coronary vascular stents, peripheral vascular stents, cerebral, urethral, ureteral, biliary, tracheal, gastrointestinal and esophageal stents), stent coverings, stent grafts, vascular grafts, valves including heart valves and vascular valves, abdominal aor
- neurostimulation systems such as spinal cord stimulation (SCS) systems, deep brain stimulation (
- the polymeric regions of the present invention correspond to an entire medical device. In other embodiments, the polymeric regions correspond to one or more portions of a medical device.
- the polymeric regions can be in the form of medical device components, in the form of one or more fibers which are incorporated into a medical device, in the form of one or more polymeric layers formed over all or only a portion of an underlying substrate, and so forth.
- Materials for use as underlying medical device substrates include ceramic, metallic and polymeric substrates. Layers can be provided over an underlying substrate at a variety of locations and in a variety of shapes (e.g., in the form of a series of rectangles, stripes, or any other continuous or non-continuous pattern).
- a “layer” of a given material is a region of that material whose thickness is small compared to both its length and width.
- a layer need not be planar, for example, taking on the contours of an underlying substrate. Layers can be discontinuous (e.g., patterned).
- polyisobutylene urethane, urea and urethane/urea copolymers in accordance with the present invention may be used to form inner or outer coatings for implantable electrical leads, may be used to form lead body components (e.g., seal O-rings, etc.), or may be used to form polymeric components of pacemakers, defibrillators or heart failure devices, among many other applications.
- lead body components e.g., seal O-rings, etc.
- the polymeric regions for use in the medical devices of the present invention may optionally contain one or more supplemental agents.
- an organically modified silicate is blended with the polymers forming the polymeric region as a supplemental agent.
- a supplemental agent may act to create a tortuous pathway for moisture thereby decreasing the moisture permeability of the region.
- silicates may maintain the strength and increase the modulus of the material.
- Supplemental agents further include agents such as alumina, silver nanoparticles, and silicate/alumina/silver nanoparticle composites.
- one or more therapeutic agents are included beneath, within (e.g., blended with), or attached to (e.g., covalently or non-covalently bound to) polymeric regions in accordance with the invention.
- therapeutic agents “Therapeutic agents,” “drugs,” “pharmaceutically active agents,” “pharmaceutically active materials,” and other related terms may be used interchangeably herein.
- a wide variety of therapeutic agents can be employed in conjunction with the present invention including those used for the treatment of a wide variety of diseases and conditions (i.e., the prevention of a disease or condition, the reduction or elimination of symptoms associated with a disease or condition, or the substantial or complete elimination of a disease or condition).
- Exemplary therapeutic agents for use in conjunction with the present invention include the following: (a) anti-thrombotic agents such as heparin, heparin derivatives, urokinase, clopidogrel, and PPack (dextrophenylalanine proline arginine chloromethylketone); (b) anti-inflammatory agents such as dexamethasone, prednisolone, corticosterone, budesonide, estrogen, sulfasalazine and mesalamine; (c) antineoplastic/antiproliferative/anti-miotic agents such as paclitaxel, 5-fluorouracil, cisplatin, vinblastine, vincristine, epothilones, endostatin, angiostatin, angiopeptin, monoclonal antibodies capable of blocking smooth muscle cell proliferation, and thymidine kinase inhibitors; (d) anesthetic agents such as lidocaine, bupivacaine and
- agents are useful for the practice of the present invention and include one or more of the following: (a) Ca-channel blockers including benzothiazapines such as diltiazem and clentiazem, dihydropyridines such as nifedipine, amlodipine and nicardapine, and phenylalkylamines such as verapamil, (b) serotonin pathway modulators including: 5-HT antagonists such as ketanserin and naftidrofuryl, as well as 5-HT uptake inhibitors such as fluoxetine, (c) cyclic nucleotide pathway agents including phosphodiesterase inhibitors such as cilostazole and dipyridamole, adenylate/Guanylate cyclase stimulants such as forskolin, as well as aden
- Typical therapeutic agent loadings range, for example, from than 1 wt % or less to 2 wt % to 5 wt % to 10 wt % to 25 wt % or more of the polymeric region.
- thermoplastic processing techniques may be used to form polymeric regions from the same. Using these techniques, a polymeric region can be formed, for instance, by (a) first providing a melt that contains polymer(s) and any other optional agents such as silicates, therapeutic agents, and so forth, and (b) subsequently cooling the melt.
- thermoplastic processing techniques include compression molding, injection molding, blow molding, spraying, vacuum forming and calendaring, extrusion into sheets, fibers, rods, tubes and other cross-sectional profiles of various lengths, and combinations of these processes. Using these and other thermoplastic processing techniques, entire devices or portions thereof can be made.
- polymeric regions can be formed, for instance, by (a) first providing a solution or dispersion that contains polymer(s) and any optional agents such as therapeutic agents, silicates and so forth, and (b) subsequently removing the solvent.
- the solvent that is ultimately selected will contain one or more solvent species, which are generally selected based on their ability to dissolve the polymer(s) that form the polymeric region, in addition to other factors, including drying rate, surface tension, etc. In certain embodiments, the solvent is selected based on its ability to dissolve or disperse the optional agents, if any.
- solvent-based techniques include, but are not limited to, solvent casting techniques, spin coating techniques, web coating techniques, spraying techniques, dipping techniques, techniques involving coating via mechanical suspension including air suspension, ink jet techniques, electrostatic techniques, and combinations of these processes.
- a polymer containing solution (where solvent-based processing is employed) or a polymer containing melt (where thermoplastic processing is employed) is applied to a substrate to form a polymeric region.
- the substrate can correspond to all or a portion of an implantable or insertable medical device to which a polymeric coating is applied, for example, by spraying, extrusion, and so forth.
- the substrate can also be, for example, a template, such as a mold, from which the polymeric region is removed after solidification.
- extrusion and co-extrusion techniques one or more polymeric regions are formed without the aid of a substrate. In a specific example, an entire medical device is extruded.
- a polymeric coating layer is co-extruded along with and underlying medical device body.
- a polymeric tube is extruded which is then assembled over a medical device substrate (e.g., on an electrical lead, either as an electrically insulating or electrically non-insulating jacket).
Abstract
Description
- This application claims priority from U.S. provisional application 61/076,327 filed Jun. 27, 2008, which is incorporated herein by reference in its entirety.
- The present invention relates to urethane, urea and urethane/urea copolymers and to medical devices containing the same.
- The use of polymeric materials in medical devices for implantation or insertion into the body of a patient is common in the practice of modern medicine. For example, polymeric materials such as silicone rubber, polyurethane, and fluoropolymers, for instance, polytetrafluoroethylene (PTFE), expanded PTFE (ePTFE) and ethylene tetrafluoroethylene (ETFE), are used as coating materials/insulation for medical leads, providing mechanical protection, electrical insulation, or both.
- As another example, drug eluting stents are known which have polymeric coatings over the stent to release a drug to counteract the effects of in-stent restenosis. Specific examples of drug eluting coronary stents include commercially available stents from Boston Scientific Corp. (TAXUS, PROMUS), Johnson & Johnson (CYPHER), and others. See S. V. Ranade et al., Acta Biomater. 2005 January; 1 (1): 137-44 and R. Virmani et al., Circulation 2004 Feb. 17, 109 (6) 701-5. Various types of polymeric materials have been used in such polymeric coatings including, for example, homopolymers such as poly(n-butyl methacrylate) and copolymers such as poly(ethylene-co-vinyl acetate), poly(vinylidene fluoride-co-hexafluoropropylene), and poly(isobutylene-co-styrene), for example, poly(styrene-b-isobutylene-b-styrene) triblock copolymers (SIBS), which are described, for instance, in U.S. Pat. No. 6,545,097 to Pinchuk et al. SIBS triblock copolymers have a soft, elastomeric low glass transition temperature (Tg) midblock and hard elevated Tg endblocks. Consequently, SIBS copolymers are thermoplastic elastomers, in other words, elastomeric (i.e., reversibly deformable) polymers that form physical crosslinks which can be reversed by melting the polymer (or, in the case of SIBS, by dissolving the polymer in a suitable solvent). SIBS is also highly biocompatible.
- The present invention pertains to polyisobutylene urethane copolymers, to polyisobutylene urea copolymers, to polyisobutylene urethane/urea copolymers, to methods of making such copolymers and to medical devices that contain such polymers.
- According to certain aspects of the invention, polyurethanes, polyureas and polyurethane/polyureas are provided, which comprise a polyisobutylene segment, an additional polymeric segment that is not a polyisobutylene segment, and a segment comprising a residue of a diisocyanate.
- According to other aspects of the invention, polyurethanes, polyureas and polyurethane/polyureas are provided, which comprise a polyisobutylene segment and end groups that comprise alkyl-, alkenyl- or alkynyl-chain-containing end groups.
- These and other aspects and embodiments as well as various advantages of the present invention will become readily apparent to those of ordinary skill in the art upon review of the Detailed Description and any Claims to follow.
- A more complete understanding of the present invention is available by reference to the following detailed description of numerous aspects and embodiments of the invention. The detailed description of the invention which follows is intended to illustrate but not limit the invention.
- As is well known, “polymers” are molecules containing multiple copies (e.g., from 5 to 10 to 25 to 50 to 100 to 250 to 500 to 1000 or more copies) of one or more constitutional units, commonly referred to as monomers. As used herein, the term “monomers” may refer to free monomers and to those that have been incorporated into polymers, with the distinction being clear from the context in which the term is used.
- Polymers may take on a number of configurations, which may be selected, for example, from linear, cyclic and branched configurations, among others. Branched configurations include star-shaped configurations (e.g., configurations in which three or more chains emanate from a single branch point), comb configurations (e.g., configurations having a main chain and a plurality of side chains, also referred to as “graft” configurations), dendritic configurations (e.g., arborescent and hyperbranched polymers), and so forth.
- As used herein, “homopolymers” are polymers that contain multiple copies of a single constitutional unit (i.e., monomer). “Copolymers” are polymers that contain multiple copies of at least two dissimilar constitutional units.
- As used herein, a “polymeric segment” or “segment” is a portion of a polymer. Segments can be unbranched or branched. Segments can contain a single type of constitutional unit (also referred to herein as “homopolymeric segments”) or multiple types of constitutional units (also referred to herein as “copolymeric segments”) which may be present, for example, in a random, statistical, gradient, or periodic (e.g., alternating) distribution.
- As used herein a soft segment is one that displays a Tg that is below body temperature, more typically from 35° C. to 20° C. to 0° C. to −25° C. to −50° C. or below. A hard segment is one that displays a Tg that is above body temperature, more typically from 40° C. to 50° C. to 75° C. to 100° C. or above. Tg can be measured by differential scanning calorimetry (DSC), dynamic mechanical analysis (DMA) and thermomechanical analysis (TMA).
- Polyurethanes are a family of copolymers that are synthesized from polyfunctional isocyanates (e.g., diisocyanates, including both aliphatic and aromatic diisocyanates) and polyols (e.g., macroglycols). Commonly employed macroglycols include polyester diols, polyether diols and polycarbonate diols. Typically, aliphatic or aromatic diols or diamines are also employed as chain extenders, for example, to impart improved physical properties to the polyurethane. Where diamines are employed as chain extenders, urea linkages are formed and the resulting polymers may be referred to as polyurethane/polyureas
- Polyureas are a family of copolymers that are synthesized from polyfunctional isocyanates and polyamines, for example, diamines such as polyester diamines, polyether diamines, polysiloxane diamines, polyhydrocarbon diamines and polycarbonate diamines. As with polyurethanes, aliphatic or aromatic diols or diamines may be employed as chain extenders.
- Urethane, urea and urethane/urea copolymers in accordance with the invention typically comprise one or more polyisobutylene segments. For example, according to certain aspects of the invention, polyisobutylene urethane, urea and urethane/urea copolymers are provided, which contain (a) one or more polyisobutylene segments, (b) one or more additional polymeric segments (other than polyisobutylene segments), and (c) one or more segments that contains one or more diisocyanate residues and, optionally, one or more chain extender residues.
- Examples of additional polymeric segments include soft polymeric segments such as polyether segments, fluoropolymer segments including fluorinated polyether segments, polyester segments, poly(acrylate) segments, poly(methacrylate) segments, polysiloxane segments and polycarbonate segments.
- Examples of soft polyether segments include linear, branched and cyclic homopoly(alkylene oxide) and copoly(alkylene oxide) segments, including homopolymeric and copolymeric segments formed from one or more of the following, among others: methylene oxide, dimethylene oxide (ethylene oxide), trimethylene oxide, propylene oxide, and tetramethylene oxide.
- Examples of soft fluoropolymer segments include perfluoroacrylate segments and fluorinated polyether segments, for example, linear, branched and cyclic homopoly(fluorinated alkylene oxide) and copoly(fluorinated alkylene oxide) segments, including homopolymeric and copolymeric segments formed from one or more of the following, among others: perfluoromethylene oxide, perfluorodimethylene oxide (perfluoroethylene oxide), perfluorotrimethylene oxide and perfluoropropylene oxide.
- Examples of soft polyester segments include linear, branched and cyclic homopolymeric and copolymeric segments formed from one or more of the following, among others: alkyleneadipates including ethyleneadipate, propyleneadipate, tetramethyleneadipate, and hexamethyleneadipate.
- Examples of soft poly(acrylate) segments include linear, branched and cyclic homopoly(acrylate) and copoly(acrylate) segments, including homopolymeric and copolymeric segments formed from one or more of the following, among others: alkyl acrylates such as methyl acrylate, ethyl acrylate, propyl acrylate, isopropyl acrylate, butyl acrylate, sec-butyl acrylate, isobutyl acrylate, 2-ethylhexyl acrylate and dodecyl acrylate
- Examples of soft poly(methacrylate) segments include linear, branched and cyclic homopoly(methacrylate) and copoly(methacrylate) segments, including homopolymeric and copolymeric segments formed from one or more of the following, among others: alkyl methacrylates such as hexyl methacrylate, 2-ethylhexyl methacrylate, octyl methacrylate, dodecyl methacrylate and octadecyl methacrylate.
- Examples of soft polysiloxane segments include linear, branched and cyclic homopolysiloxane and copolysiloxane segments, including homopolymeric and copolymeric segments formed from one or more of the following, among others: dimethyl siloxane, diethyl siloxane, and methylethyl siloxane.
- Examples of soft polycarbonate segments include those comprising one or more types of carbonate units,
- where R may be selected from linear, branched and cyclic alkyl groups. Specific examples include homopolymeric and copolymeric segments formed from one or more of the following monomers, among others: ethylene carbonate, propylene carbonate, and hexamethylene carbonate.
- Examples of additional polymeric segments also include hard polymeric segments such as poly(vinyl aromatic) segments, poly(alkyl acrylate) and poly(alkyl methacrylate) segments.
- Examples of hard poly(vinyl aromatic) segments include linear, branched and cyclic homopoly(vinyl aromatic) and copoly(vinyl aromatic) segments, including homopolymeric and copolymeric segments formed from one or more of the following vinyl aromatic monomers, among others: styrene, 2-vinyl naphthalene, alpha-methyl styrene, p-methoxystyrene, p-acetoxystyrene, 2-methylstyrene, 3-methylstyrene and 4-methylstyrene.
- Examples of hard poly(acrylate) segments include linear, branched and cyclic homopoly(alkyl acrylate) and copoly(alkyl acrylate) segments, including homopolymeric and copolymeric segments formed from one or more of the following acrylate monomers, among others: tert-butyl acrylate, hexyl acrylate and isobornyl acrylate.
- Examples of hard poly(alkyl methacrylate) segments include linear, branched and cyclic homopoly(alkyl methacrylate) and copoly(alkyl methacrylate) segments, including homopolymeric and copolymeric segments formed from one or more of the following alkyl methacrylate monomers, among others: methyl methacrylate, ethyl methacrylate, isopropyl methacrylate, isobutyl methacrylate, t-butyl methacrylate, and cyclohexyl methacrylate.
- The various polymeric segments described herein can vary widely in molecular weight, but typically are composed of between 2 and 100 repeat units (monomer units).
- The various polymeric segments described herein can be incorporated into the polyurethanes, polyureas and polyurethane/polyureas of the invention by providing them in the form of polyols (e.g., diols, triols, etc.) and polyamines (e.g., diamines, triamines, etc.). Although the discussion to follow is generally based on the use of polyols, it is to be understood that analogous methods may be performed and analogous compositions may be created using polyamines and polyol/polyamine combinations.
- Specific examples of polyisobutylene polyols include linear polyisobutylene diols and branched (three-arm) polyisobutylene triols. See, e.g., J. P. Kennedy et al., “Designed Polymers by Carbocationic Macromolecular Engineering: Theory and Practice,” Hanser Publishers 1991, pp. 191-193, Joseph P. Kennedy, Journal of Elastomers and Plastics 1985 17: 82-88, and the references cited therein. Further examples of polyisobutylene polyols include poly(styrene-co-isobutylene) diols include poly(styrene-b-isobutylene-b-styrene) diols which may be formed, for example, using methods analogous to those described in the preceding Kennedy references. Examples of polyether polyols include polytetramethylene oxide diols, which are available from various sources including Signa-Aldrich Co., Saint Louis, Mo., USA and E. I. duPont de Nemours and Co., Wilmington, Del., USA. Examples of polysiloxane polyols include polydimethylsiloxane diols, available from various sources including Dow Corning Corp., Midland Mich., USA, Chisso Corp., Tokyo, Japan. Examples of polycarbonate polyols include polyhexamethylene carbonate diols such as those available from Sigma-Aldrich Co. Examples of polyfluoroalkylene oxide diols include ZDOLTX, Ausimont, Bussi, Italy, a copolyperfluoroalkylene oxide diol containing a random distribution of —CF2CF2O— and —CF2O— units, end-capped by ethoxylated units, i.e., H(OCH2CH2)nOCH2CF2O(CF2CF2O)p(CF2O)qCF2CH2—O—(CH2CH2O)nH, where n, p and q are integers. Polystyrene diol (α,ω-dihydroxy-terminated polystyrene) of varying molecular weight is available from Polymer Source, Inc., Montreal, Canada. Polystyrene diols and three-arm triols may be formed, for example, using procedures analogous to those described in M. WeiBmüller et al., “Preparation and end-linking of hydroxyl-terminated polystyrene star macromolecules,” Macromolecular Chemistry and Physics 200 (3), 1999, 541-551.
- In some embodiments, polyols (e.g., diols, triols, etc.) are employed which are based on block copolymers. Examples of such block copolymer polyols include poly(tetramethylene oxide-b-isobutylene) diol, poly(tetramethylene oxide-b-isobutylene-b-alkylene oxide) diol, poly(dimethyl siloxane-b-isobutylene) diol, poly(dimethyl siloxane-b-isobutylene-b-dimethyl siloxane) diol, poly(hexamethylene carbonate-b-isobutylene) diol, poly(hexamethylene carbonate-b-isobutylene-b-hexamethylene carbonate) diol, poly(methyl methacrylate-b-isobutylene) diol, poly(methyl methacrylate-b-isobutylene-b-methyl methacrylate) diol, poly(styrene-b-isobutylene) diol and poly(styrene-b-isobutylene-b-styrene) diol (SIBS diol).
- As noted above, polyisobutylene urethane, urea and urethane/urea copolymers in accordance with the invention typically contain one or more segments that contain one or more diisocyanate residues and, optionally, one or more chain extender residues.
- Diisocyanates for use in forming the urethane, urea and urethane/urea copolymers of the invention include aromatic and non-aromatic (e.g., aliphatic) diisocyanates. Aromatic diisocyanates may be selected from suitable members of the following, among others: 4,4′-methylenediphenyl diisocyanate (MDI), 2,4- and/or 2,6-toluene diisocyanate (TDI), 1,5-naphthalene diisocyanate (NDI), para-phenylene diisocyanate, 3,3′-tolidene-4,4′-diisocyanate and 3,3′-dimethyl-diphenylmethane-4,4′-diisocyanate. Non-aromatic diisocyanates may be selected from suitable members of the following, among others: 1,6-hexamethylene diisocyanate (HDI), 4,4′-dicyclohexylmethane diisocyanate, 3-isocyanatomethyl-3,5,5-trimethylcyclohexyl isocyanate (isophorone diisocyanate or IPDI), cyclohexyl diisocyanate, and 2,2,4-trimethyl-1,6-hexamethylene diisocyanate (TMDI).
- Optional chain extenders are typically aliphatic or aromatic diols (in which case a urethane bond is formed upon reaction with an isocyanate group) or aliphatic or aromatic diamines (in which case a urea bond is formed upon reaction with an isocyanate group). Chain extenders may be selected from suitable members of the following, among others: alpha,omega-alkane diols such as ethylene glycol (1,2-ethane diol), 1,4-butanediol, 1,6-hexanediol, alpha,omega-alkane diamines, such as ethylene diamine, dibutylamine (1,4-butane diamine) and 1,6-hexanediamine, or 4,4′-methylene bis(2-chloroaniline).
- Chain extenders may be also selected from suitable members of the following, among others: short chain diol polymers (e.g., alpha,omega-dihydroxy-terminated polymers having a molecular weight less than or equal to 1000) based on hard and soft polymeric segments (more typically soft polymeric segments) such as those described above, including short chain polyisobutylene diols, short chain polyether polyols such as polytetramethylene oxide diols, short chain polysiloxane diols such as polydimethylsiloxane diols, short chain polycarbonate diols such as polyhexamethylene carbonate diols, short chain poly(fluorinated ether) diols, short chain polyester diols, short chain polyacrylate diols, short chain polymethacrylate diols, and short chain poly(vinyl aromatic) diols. As is known in the polyurethane art, chain extenders can increase the hard segment length (or, stated another way, can increase the ratio of hard segment material to soft segment material in the urethane, urea or urethane/urea polymer), which can in turn result in a polymer with higher modulus, lower elongation at break and increased strength.
- In certain other aspects of the invention, polyisobutylene urethane, urea and urethane/urea copolymers are provided, which comprise (a) one or more polyisobutylene segments, (b) optionally, one or more additional segments other than polyisobutylene segments, (c) one or more diisocyanate residues, (d) optionally, one or more chain extender residues, and (e) end groups that comprise alkyl, alkenyl or alkynyl chains ranging from 1 to 18 carbons in length. For example, such end groups may be selected from [—CH2]n—CH3 groups, [—CH2]n—CF3 groups, [—CH2]n—C6H5 groups (i.e., [—CH2]n-ph) and combinations thereof, among others, where n ranges from 1 to 17 (e.g., 1 to 2 to 3 to 4 to 5 to 6 to 7 to 8 to 9 to 10 to 11 to 12 to 13 to 14 to 15 to 16 to 17).
- Polyisobutylene urethane, urea and urethane/urea copolymers in accordance with the invention may the synthesized, for example, in bulk or using a suitable solvent (e.g., one capable or dissolving the various species that participate in the polymerization reaction).
- Various synthetic strategies may be employed to create polyisobutylene urethane, urea and urethane/urea polymers in accordance with the invention. These strategies typically involved the reaction of (a) one or more polyol (commonly diol) species and one or more polyisocyanate (commonly diisocyanate) species, (b) one or more polyamine (commonly diamine) species and one or more polyisocyanate species, or (c) one or more polyol species, one or more polyamine species and one or more polyisocyanate species. Reaction may be conducted, for example, in organic solvents, or using supercritical CO2 as a solvent. Ionomers can be used for polymer precipitation.
- As previously indicated, although the discussion to follow is generally based on the use of polyols, it is to be understood that analogous methods may be performed and analogous compositions may be created using polyamines and polyol/polyamine combinations.
- For example, in certain embodiments, a one step method may be employed in which a first macrodiol (M1) (e.g., a block copolymer diol such as SIBS diol, etc.) and a diisocyante (DI) (e.g., MDI, TDI, etc.) are reacted in a single step. Molar ratio of diisocyanate relative to the first macrodiol is 1:1. Using this technique a polyurethane having alternating macrodiol and diisocyante residues, i.e., -[DI-M1-]n, where n is an integer, may be formed. In some embodiments, a diol or diamine chain extender (CE) (e.g., 1,2-ethane diol, 1,4-butanediol, 1,6-hexanediol, etc.) is included in the reaction mixture, in which case the molar ratio of diisocyanate relative to the combination of the first macrodiol and the chain extender is 1:1. For example, the ratio DI:M1:CE may equal 2:1:1, may equal 2:1.5:0.5, may equal 2:0.5:1.5, among many other possibilities. Where a ratio of DI:M1:CE equal to 2:1:1 is employed, a polyurethane having the following structure may be formed -[DI-M1-DI-CE-]n. Reactions of this type have been reported to follow a statistical distribution, so M1 and CE residues are not likely to be perfectly alternating as shown. See, e.g., F. Wang, “Polydimethylsiloxane Modification of Segmented Thermoplastic Polyurethanes and Polyureas, Ph.D. dissertation, Virginia Polytechnic Institute and State University, Apr. 13, 1998.
- In other embodiments, a two-step reaction is employed wherein the first macrodiol and diisocyante are reacted in a single step at a DI:M1 molar ratio of ≧2:1 in order to form isocyanate-end-capped “prepolymers,” DI-M1-DI. Then, in a second step, a chain extender is added, along with additional diisocyanate, if required to maintain an overall molar ratio of diisocyanate relative to the combination of the first macrodiol and the chain extender of 1:1. As above, where a molar ratio of DI:M1:CE equal to 2:1:1 is employed, a polyurethane having the following structure may be formed -[DI-M1-DI-CE-]n, although the M1 and CE residues may not be perfectly alternating as shown. Due to enhanced reaction control, polyurethanes made by the two-step method tend to have a more regular structure than corresponding polyurethanes made by the one step method.
- In certain other embodiments, a one step method may be employed in which a first macrodiol (M1) (e.g., a polyisobutylene diol, a SIBS diol, etc.), a second macrodiol (M2) (e.g., a polyether diol, a fluoropolymer diol, a polysiloxane diol, a polycarbonate diol, a polyester diol, a polyacrylate diol, a polymethacrylate diol, a polystyrene diol, etc.) and a diisocyante (DI) (e.g., MDI, TDI, etc.) are reacted in a single step. Molar ratio of diisocyanate relative to the first and second diols is 1:1. For example, the ratio DI:M1:M2 may equal 2:1:1, may equal 2:1.5:0.5, may equal 2:0.5:1.5, among many other possibilities. Where a ratio of DI:M1:M2 equal to 2:1:1 is employed, a polyurethane having the following structure may be formed -[DI-M1-DI-M2-]n although the chains are unlikely to be perfectly alternating as shown. In some embodiments, a chain extender is added to the reaction mixture, such that the molar ratio of diisocyanate relative to the first and second macrodiols and chain extender is 1:1. For example, the ratio DI:M1:M2:CE may equal 4:1:1:2, may equal 2:0.67:0.33:1, may equal 2:0.33:0.67:1, or may equal 5:1:1:3, among many other possibilities. Where a ratio of DI:M1:M2:CE equal to 4:1:1:2 is employed, a polyurethane having the following structure may be formed -[DI-M1-DI-CE-DI-M2-DI-CE-]n, although the chains are unlikely to be perfectly alternating as shown.
- In some embodiments, a two-step method is employed in which first and second macrodiols and diisocyante are reacted in a ratio of DI:M1:M2 of ≧2:1:1 in a first step to form isocyanate capped first and second macrodiols, for example DI-M1-DI and DI-M2-DI. In a second step, a chain extender is added which reacts with the isocyanate end caps of the macrodiols. In some embodiments, the number of moles of hydroxyl or amine groups of the chain extender may exceed the number of moles of isocyanate end caps for the macrodiols, in which case additional diisocyante may be added in the second step as needed to maintain a suitable overall stoichiometry. As above, the molar ratio of diisocyanate relative to the total of the first macrodiol, second macrodiol, and chain extender is typically 1:1, for example, DI:M1:M2:CE may equal 4:1:1:2, which may in theory yield an idealized polyurethane having the following repeat structure -[DI-M1-DI-CE-DI-M2-DI-CE-]n, although the chains are unlikely to be perfectly alternating as shown. In other examples, the DI:M1:M2:CE ratio may equal 4:1.5:0.5:2 or may equal 5:1:1:3, among many other possibilities.
- In some embodiments, three, four or more steps may be employed in which a first macrodiol and diisocyante are reacted in a first step to form isocyanate capped first macrodiol, typically in a DI:M1 ratio of ≧2:1 such that isocyanate end caps are formed at each end of the first macrodiol (although other ratios are possible including a DI:M1 ratio of 1:1, which would yield an average of one isocyanate end caps per macrodiol). This step is followed by second step in which the second macrodiol is added such that it reacts with one or both isocyanate end caps of the isocyanate capped first macrodiol. Depending on the relative ratios of DI, M1 and M2, this step may be used to create structures (among other statistical possibilities) such as M2-DI-M1-DI-M2 (for a DI:M1:M2 ratio of 2:1:2), M2-DI-M1-DI (for a DI:M1:M2 ratio of 2:1:1), or M1-DI-M2 (for a DI:M1:M2 ratio of 1:1:1).
- In certain embodiments, a mixed macrodiol prepolymer, such as one of those in the prior paragraph, among others (e.g., M2-DI-M1-DI-M2, M1-DI-M2-DI-M1, DI-M1-DI-M2, etc.) is reacted simultaneously with a diol or diamine chain extender and a diisocyanate, as needed to maintain stoichiometry. For example, the chain extension process may be used to create idealized structures along the following lines, among others: -[DI-M2-DI-M1-DI-M2-DI-CE-]n, -[DI-M1-DI-M2-DI-M1-DI-CE-]n or -[DI-M1-DI-M2-DI-CE-]n, although it is again noted that the chains are not likely to be perfectly alternating as shown.
- In certain other embodiments, a mixed macrodiol prepolymer is reacted with sufficient diisocyanate to form isocyanate end caps for the mixed macrodiol prepolymer (e.g., yielding DI-M2-DI-M1-DI-M2-DI, DI-M1-DI-M2-DI-M1-DI or DI-M1-DI-M2-DI, among other possibilities). This isocyanate-end-capped mixed macrodiol can then be reacted with a diol or diamine chain extender (and a diisocyanate, as needed to maintain stoichiometry). For example, the isocyanate-end-capped mixed macrodiol can be reacted with an equimolar amount of a chain extender to yield idealized structures of the following formulae, among others: -[DI-M2-DI-M1-DI-M2-DI-CE-]n, -[DI-M1-DI-M2-DI-M1-DI-CE-]n or -[DI-M1-DI-M2-DI-CE-]n.
- As noted above, in some embodiments of the invention, urethane, urea and urethane/urea molecules having alkyl-, alkenyl- or alkynyl-chain-containing end groups such as [—CH2]n—CH3 or [—CH2]n—CF3 or [—CH2]n—C6H5 end groups, among many others, are formed. For example, such polymers may be formed by reacting a urethane, urea or urethane/urea copolymer such as one of those described above with a molecule of the formula HO[—CH2]n—CH3 or of the formula
- HO[—CH2]n—CF3 or of the formula HO[—CH2]n—C6H5, preferably after ensuring that the urethane, urea or urethane/urea copolymer is provided with isocyanate end caps.
- In accordance with various aspects of the invention, implantable and insertable medical devices are provided, which contain one or more polymeric regions containing one or more polyisobutylene urethane, urea or urethane/urea copolymers. As used herein, a “polymeric region” is a region (e.g., an entire device, a device component, a device coating layer, etc.) that contains polymers, for example, from 50 wt % or less to 75 wt % to 90 wt % to 95 wt % to 97.5 wt % to 99 wt % or more polymers.
- Examples of medical devices for the practice of the present invention include implantable or insertable medical devices, for example, implantable electrical stimulation systems including neurostimulation systems such as spinal cord stimulation (SCS) systems, deep brain stimulation (DBS) systems, peripheral nerve stimulation (PNS) systems, gastric nerve stimulation systems, cochlear implant systems, and retinal implant systems, among others, and cardiac systems including implantable pacemaker systems, implantable cardioverter-defibrillators (ICD's), and cardiac resynchronization and defibrillation (CRDT) devices, including polymeric components for leads including lead insulation, outer body insulation, and components for the foregoing implantable electrical stimulation systems, stents (including coronary vascular stents, peripheral vascular stents, cerebral, urethral, ureteral, biliary, tracheal, gastrointestinal and esophageal stents), stent coverings, stent grafts, vascular grafts, valves including heart valves and vascular valves, abdominal aortic aneurysm (AAA) devices (e.g., AAA stents, AAA grafts, etc.), vascular access ports, dialysis ports, embolization devices including cerebral aneurysm filler coils (including Guglilmi detachable coils and metal coils), embolic agents, tissue bulking devices, catheters (e.g., renal or vascular catheters such as balloon catheters and various central venous catheters), guide wires, balloons, filters (e.g., vena cava filters and mesh filters for distil protection devices), septal defect closure devices, myocardial plugs, patches, ventricular assist devices including left ventricular assist hearts and pumps, total artificial hearts, shunts, anastomosis clips and rings, and tissue engineering scaffolds for cartilage, bone, skin and other in vivo tissue regeneration, urethral slings, hernia “meshes”, artificial ligaments, orthopedic prosthesis, dental implants, biopsy devices, as well as any coated substrate (which can comprise, for example, metals, polymers, ceramics and combinations thereof) that is implanted or inserted into the body.
- In some embodiments, the polymeric regions of the present invention correspond to an entire medical device. In other embodiments, the polymeric regions correspond to one or more portions of a medical device. For instance, the polymeric regions can be in the form of medical device components, in the form of one or more fibers which are incorporated into a medical device, in the form of one or more polymeric layers formed over all or only a portion of an underlying substrate, and so forth. Materials for use as underlying medical device substrates include ceramic, metallic and polymeric substrates. Layers can be provided over an underlying substrate at a variety of locations and in a variety of shapes (e.g., in the form of a series of rectangles, stripes, or any other continuous or non-continuous pattern). As used herein a “layer” of a given material is a region of that material whose thickness is small compared to both its length and width. As used herein a layer need not be planar, for example, taking on the contours of an underlying substrate. Layers can be discontinuous (e.g., patterned).
- In certain preferred embodiments, polyisobutylene urethane, urea and urethane/urea copolymers in accordance with the present invention may be used to form inner or outer coatings for implantable electrical leads, may be used to form lead body components (e.g., seal O-rings, etc.), or may be used to form polymeric components of pacemakers, defibrillators or heart failure devices, among many other applications.
- In addition to one or more polymers, the polymeric regions for use in the medical devices of the present invention may optionally contain one or more supplemental agents.
- For example, in some embodiments, an organically modified silicate is blended with the polymers forming the polymeric region as a supplemental agent. Such an agent may act to create a tortuous pathway for moisture thereby decreasing the moisture permeability of the region. Moreover, such silicates may maintain the strength and increase the modulus of the material. Supplemental agents further include agents such as alumina, silver nanoparticles, and silicate/alumina/silver nanoparticle composites.
- In some embodiments, one or more therapeutic agents are included beneath, within (e.g., blended with), or attached to (e.g., covalently or non-covalently bound to) polymeric regions in accordance with the invention. “Therapeutic agents,” “drugs,” “pharmaceutically active agents,” “pharmaceutically active materials,” and other related terms may be used interchangeably herein.
- A wide variety of therapeutic agents can be employed in conjunction with the present invention including those used for the treatment of a wide variety of diseases and conditions (i.e., the prevention of a disease or condition, the reduction or elimination of symptoms associated with a disease or condition, or the substantial or complete elimination of a disease or condition).
- Exemplary therapeutic agents for use in conjunction with the present invention include the following: (a) anti-thrombotic agents such as heparin, heparin derivatives, urokinase, clopidogrel, and PPack (dextrophenylalanine proline arginine chloromethylketone); (b) anti-inflammatory agents such as dexamethasone, prednisolone, corticosterone, budesonide, estrogen, sulfasalazine and mesalamine; (c) antineoplastic/antiproliferative/anti-miotic agents such as paclitaxel, 5-fluorouracil, cisplatin, vinblastine, vincristine, epothilones, endostatin, angiostatin, angiopeptin, monoclonal antibodies capable of blocking smooth muscle cell proliferation, and thymidine kinase inhibitors; (d) anesthetic agents such as lidocaine, bupivacaine and ropivacaine; (e) anti-coagulants such as D-Phe-Pro-Arg chloromethyl ketone, an RGD peptide-containing compound, heparin, hirudin, antithrombin compounds, platelet receptor antagonists, anti-thrombin antibodies, anti-platelet receptor antibodies, aspirin, prostaglandin inhibitors, platelet inhibitors and tick antiplatelet peptides; (f) vascular cell growth promoters such as growth factors, transcriptional activators, and translational promotors; (g) vascular cell growth inhibitors such as growth factor inhibitors, growth factor receptor antagonists, transcriptional repressors, translational repressors, replication inhibitors, inhibitory antibodies, antibodies directed against growth factors, bifunctional molecules consisting of a growth factor and a cytotoxin, bifunctional molecules consisting of an antibody and a cytotoxin; (h) protein kinase and tyrosine kinase inhibitors (e.g., tyrphostins, genistein, quinoxalines); (i) prostacyclin analogs; (j) cholesterol-lowering agents; (k) angiopoietins; (l) antimicrobial agents such as triclosan, cephalosporins, aminoglycosides and nitrofurantoin; (m) cytotoxic agents, cytostatic agents and cell proliferation affectors; (n) vasodilating agents; (o) agents that interfere with endogenous vasoactive mechanisms; (p) inhibitors of leukocyte recruitment, such as monoclonal antibodies; (q) cytokines; (r) hormones; (s) inhibitors of HSP 90 protein (i.e., Heat Shock Protein, which is a molecular chaperone or housekeeping protein and is needed for the stability and function of other client proteins/signal transduction proteins responsible for growth and survival of cells) including geldanamycin, (t) alpha receptor antagonist (such as doxazosin, Tamsulosin) and beta receptor agonists (such as dobutamine, salmeterol), beta receptor antagonist (such as atenolol, metaprolol, butoxamine), angiotensin-II receptor antagonists (such as losartan, valsartan, irbesartan, candesartan and telmisartan), and antispasmodic drugs (such as oxybutynin chloride, flavoxate, tolterodine, hyoscyamine sulfate, diclomine) (u) bARKct inhibitors, (v) phospholamban inhibitors, (w) Serca 2 gene/protein, (x) immune response modifiers including aminoquizolines, for instance, imidazoquinolines such as resiquimod and imiquimod, (y) human apolioproteins (e.g., AI, AII, AIII, AIV, AV, etc.), (z) selective estrogen receptor modulators (SERMs) such as raloxifene, lasofoxifene, arzoxifene, miproxifene, ospemifene, PKS 3741, MF 101 and SR 16234, (aa) PPAR agonists, including PPAR-alpha, gamma and delta agonists, such as rosiglitazone, pioglitazone, netoglitazone, fenofibrate, bexaotene, metaglidasen, rivoglitazone and tesaglitazar, (bb) prostaglandin E agonists, including PGE2 agonists, such as alprostadil or ONO 8815Ly, (cc) thrombin receptor activating peptide (TRAP), (dd) vasopeptidase inhibitors including benazepril, fosinopril, lisinopril, quinapril, ramipril, imidapril, delapril, moexipril and spirapril, (ee) thymosin beta 4, (ff) phospholipids including phosphorylcholine, phosphatidylinositol and phosphatidylcholine, (gg) VLA-4 antagonists and VCAM-1 antagonists, (hh) non-fouling, protein resistant agents such as polyethyelene glycol and (ii) prohealing agents.
- Numerous therapeutic agents, not necessarily exclusive of those listed above, have been identified as candidates for vascular treatment regimens, for example, as agents targeting restenosis (antirestenotics). Such agents are useful for the practice of the present invention and include one or more of the following: (a) Ca-channel blockers including benzothiazapines such as diltiazem and clentiazem, dihydropyridines such as nifedipine, amlodipine and nicardapine, and phenylalkylamines such as verapamil, (b) serotonin pathway modulators including: 5-HT antagonists such as ketanserin and naftidrofuryl, as well as 5-HT uptake inhibitors such as fluoxetine, (c) cyclic nucleotide pathway agents including phosphodiesterase inhibitors such as cilostazole and dipyridamole, adenylate/Guanylate cyclase stimulants such as forskolin, as well as adenosine analogs, (d) catecholamine modulators including α-antagonists such as prazosin and bunazosine, β-antagonists such as propranolol and α/β-antagonists such as labetalol and carvedilol, (e) endothelin receptor antagonists such as bosentan, sitaxsentan sodium, atrasentan, endonentan, (f) nitric oxide donors/releasing molecules including organic nitrates/nitrites such as nitroglycerin, isosorbide dinitrate and amyl nitrite, inorganic nitroso compounds such as sodium nitroprusside, sydnonimines such as molsidomine and linsidomine, nonoates such as diazenium diolates and NO adducts of alkanediamines, S-nitroso compounds including low molecular weight compounds (e.g., S-nitroso derivatives of captopril, glutathione and N-acetyl penicillamine) and high molecular weight compounds (e.g., S-nitroso derivatives of proteins, peptides, oligosaccharides, polysaccharides, synthetic polymers/oligomers and natural polymers/oligomers), as well as C-nitroso-compounds, O-nitroso-compounds, N-nitroso-compounds and L-arginine, (g) Angiotensin Converting Enzyme (ACE) inhibitors such as cilazapril, fosinopril and enalapril, (h) ATII-receptor antagonists such as saralasin and losartin, (i) platelet adhesion inhibitors such as albumin and polyethylene oxide, (j) platelet aggregation inhibitors including cilostazole, aspirin and thienopyridine (ticlopidine, clopidogrel) and GP IIb/IIIa inhibitors such as abciximab, epitifibatide and tirofiban, (k) coagulation pathway modulators including heparinoids such as heparin, low molecular weight heparin, dextran sulfate and β-cyclodextrin tetradecasulfate, thrombin inhibitors such as hirudin, hirulog, PPACK (D-phe-L-propyl-L-arg-chloromethylketone) and argatroban, FXa inhibitors such as antistatin and TAP (tick anticoagulant peptide), Vitamin K inhibitors such as warfarin, as well as activated protein C, (l) cyclooxygenase pathway inhibitors such as aspirin, ibuprofen, flurbiprofen, indomethacin and sulfinpyrazone, (m) natural and synthetic corticosteroids such as dexamethasone, prednisolone, methprednisolone and hydrocortisone, (n) lipoxygenase pathway inhibitors such as nordihydroguairetic acid and caffeic acid, (o) leukotriene receptor antagonists, (p) antagonists of E- and P-selectins, (q) inhibitors of VCAM-1 and ICAM-1 interactions, (r) prostaglandins and analogs thereof including prostaglandins such as PGE1 and PGI2 and prostacyclin analogs such as ciprostene, epoprostenol, carbacyclin, iloprost and beraprost, (s) macrophage activation preventers including bisphosphonates, (t) HMG-CoA reductase inhibitors such as lovastatin, pravastatin, atorvastatin, fluvastatin, simvastatin and cerivastatin, (u) fish oils and omega-3-fatty acids, (v) free-radical scavengers/antioxidants such as probucol, vitamins C and E, ebselen, trans-retinoic acid SOD (orgotein) and SOD mimics, verteporfin, rostaporfin, AGI 1067, and M40419, (w) agents affecting various growth factors including FGF pathway agents such as bFGF antibodies and chimeric fusion proteins, PDGF receptor antagonists such as trapidil, IGF pathway agents including somatostatin analogs such as angiopeptin and ocreotide, TGF-β pathway agents such as polyanionic agents (heparin, fucoidin), decorin, and TGF-β antibodies, EGF pathway agents such as EGF antibodies, receptor antagonists and chimeric fusion proteins, TNF-α pathway agents such as thalidomide and analogs thereof, Thromboxane A2 (TXA2) pathway modulators such as sulotroban, vapiprost, dazoxiben and ridogrel, as well as protein tyrosine kinase inhibitors such as tyrphostin, genistein and quinoxaline derivatives, (x) matrix metalloprotease (MMP) pathway inhibitors such as marimastat, ilomastat, metastat, batimastat, pentosan polysulfate, rebimastat, incyclinide, apratastat, PG 116800, RO 1130830 or ABT 518, (y) cell motility inhibitors such as cytochalasin B, (z) antiproliferative/antineoplastic agents including antimetabolites such as purine analogs (e.g., 6-mercaptopurine or cladribine, which is a chlorinated purine nucleoside analog), pyrimidine analogs (e.g., cytarabine and 5-fluorouracil) and methotrexate, nitrogen mustards, alkyl sulfonates, ethylenimines, antibiotics (e.g., daunorubicin, doxorubicin), nitrosoureas, cisplatin, agents affecting microtubule dynamics (e.g., vinblastine, vincristine, colchicine, Epo D, paclitaxel and epothilone), caspase activators, proteasome inhibitors, angiogenesis inhibitors (e.g., endostatin, angiostatin and squalamine), olimus family drugs (e.g., sirolimus, everolimus, tacrolimus, zotarolimus, etc.), cerivastatin, flavopiridol and suramin, (aa) matrix deposition/organization pathway inhibitors such as halofuginone or other quinazolinone derivatives, pirfenidone and tranilast, (bb) endothelialization facilitators such as VEGF and RGD peptide, (cc) blood rheology modulators such as pentoxifylline and (dd) glucose cross-link breakers such as alagebrium chloride (ALT-711).
- Where a therapeutic agent is present, a wide range of loadings may be used in conjunction with the medical devices of the present invention. Typical therapeutic agent loadings range, for example, from than 1 wt % or less to 2 wt % to 5 wt % to 10 wt % to 25 wt % or more of the polymeric region.
- Numerous techniques are available for forming polymeric regions in accordance with the present invention.
- For example, where the polyisobutylene urethane, urea or urethane/urea copolymers of the invention have thermoplastic characteristics, a variety of standard thermoplastic processing techniques may be used to form polymeric regions from the same. Using these techniques, a polymeric region can be formed, for instance, by (a) first providing a melt that contains polymer(s) and any other optional agents such as silicates, therapeutic agents, and so forth, and (b) subsequently cooling the melt. Examples of thermoplastic processing techniques include compression molding, injection molding, blow molding, spraying, vacuum forming and calendaring, extrusion into sheets, fibers, rods, tubes and other cross-sectional profiles of various lengths, and combinations of these processes. Using these and other thermoplastic processing techniques, entire devices or portions thereof can be made.
- Other processing techniques besides thermoplastic processing techniques may also be used to form the polymeric regions of the present invention, including solvent-based techniques. Using these techniques, polymeric regions can be formed, for instance, by (a) first providing a solution or dispersion that contains polymer(s) and any optional agents such as therapeutic agents, silicates and so forth, and (b) subsequently removing the solvent. The solvent that is ultimately selected will contain one or more solvent species, which are generally selected based on their ability to dissolve the polymer(s) that form the polymeric region, in addition to other factors, including drying rate, surface tension, etc. In certain embodiments, the solvent is selected based on its ability to dissolve or disperse the optional agents, if any. Thus, optional agents such as therapeutic agents, silicates, and so forth may be dissolved or dispersed in the coating solution. Preferred solvent-based techniques include, but are not limited to, solvent casting techniques, spin coating techniques, web coating techniques, spraying techniques, dipping techniques, techniques involving coating via mechanical suspension including air suspension, ink jet techniques, electrostatic techniques, and combinations of these processes.
- In some embodiments of the invention, a polymer containing solution (where solvent-based processing is employed) or a polymer containing melt (where thermoplastic processing is employed) is applied to a substrate to form a polymeric region. For example, the substrate can correspond to all or a portion of an implantable or insertable medical device to which a polymeric coating is applied, for example, by spraying, extrusion, and so forth. The substrate can also be, for example, a template, such as a mold, from which the polymeric region is removed after solidification. In other embodiments, for example, extrusion and co-extrusion techniques, one or more polymeric regions are formed without the aid of a substrate. In a specific example, an entire medical device is extruded. In another example, a polymeric coating layer is co-extruded along with and underlying medical device body. In another example, a polymeric tube is extruded which is then assembled over a medical device substrate (e.g., on an electrical lead, either as an electrically insulating or electrically non-insulating jacket).
- Although various embodiments are specifically illustrated and described herein, it will be appreciated that modifications and variations of the present invention are covered by the above teachings and are within the purview of the appended claims without departing from the spirit and intended scope of the invention.
Claims (26)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/492,440 US20090326077A1 (en) | 2008-06-27 | 2009-06-26 | Polyisobutylene urethane, urea and urethane/urea copolymers and medical devices containing the same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7632708P | 2008-06-27 | 2008-06-27 | |
US12/492,440 US20090326077A1 (en) | 2008-06-27 | 2009-06-26 | Polyisobutylene urethane, urea and urethane/urea copolymers and medical devices containing the same |
Publications (1)
Publication Number | Publication Date |
---|---|
US20090326077A1 true US20090326077A1 (en) | 2009-12-31 |
Family
ID=41077669
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/492,483 Active 2029-12-25 US8324290B2 (en) | 2008-06-27 | 2009-06-26 | Polyisobutylene urethane, urea and urethane/urea copolymers and medical devices containing the same |
US12/492,440 Abandoned US20090326077A1 (en) | 2008-06-27 | 2009-06-26 | Polyisobutylene urethane, urea and urethane/urea copolymers and medical devices containing the same |
US13/618,148 Active US8501831B2 (en) | 2008-06-27 | 2012-09-14 | Polyisobutylene urethane, urea and urethane/urea copolymers and medical devices containing the same |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/492,483 Active 2029-12-25 US8324290B2 (en) | 2008-06-27 | 2009-06-26 | Polyisobutylene urethane, urea and urethane/urea copolymers and medical devices containing the same |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/618,148 Active US8501831B2 (en) | 2008-06-27 | 2012-09-14 | Polyisobutylene urethane, urea and urethane/urea copolymers and medical devices containing the same |
Country Status (6)
Country | Link |
---|---|
US (3) | US8324290B2 (en) |
EP (1) | EP2291204A1 (en) |
JP (1) | JP5592882B2 (en) |
CN (1) | CN102131530A (en) |
AU (1) | AU2009262097B2 (en) |
WO (2) | WO2009158609A1 (en) |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090187162A1 (en) * | 2006-05-31 | 2009-07-23 | Kaneka Corporation | Catheter Tube and Catheter Comprising the Tube |
US20100023104A1 (en) * | 2008-06-27 | 2010-01-28 | Cardiac Pacemakers, Inc. | Polyisobutylene urethane, urea and urethane/urea copolymers and medical devices containing the same |
US20100166820A1 (en) * | 2008-12-31 | 2010-07-01 | Boston Scientific Scimed, Inc. | Copolymers having polyisobutylene and biodegradable polymer segments |
US20100179298A1 (en) * | 2009-01-12 | 2010-07-15 | University Of Massachusetts Lowell | Polyisobutylene-Based Polyurethanes |
US20110054581A1 (en) * | 2009-09-02 | 2011-03-03 | Shrojalkumar Desai | Medical devices including polyisobutylene based polymers and derivatives thereof |
US20110054580A1 (en) * | 2009-09-02 | 2011-03-03 | Shrojalkumar Desai | Polyisobutylene urethane, urea and urethane/urea copolymers and medical leads containing the same |
US20110152989A1 (en) * | 2009-12-23 | 2011-06-23 | Pacesetter, Inc. | Soft abrasion-resistant polyisobutylene urethane copolymers |
US20130041108A1 (en) * | 2011-05-19 | 2013-02-14 | Joseph P. Kennedy | Polymers having both hard and soft segments, and process for making same |
US8660663B2 (en) | 2010-12-20 | 2014-02-25 | Cardiac Pacemakers, Inc. | Lead having a conductive polymer conductor |
US8903506B2 (en) | 2011-08-12 | 2014-12-02 | Cardiac Pacemakers | Method for coating devices using electrospinning and melt blowing |
US8927660B2 (en) | 2009-08-21 | 2015-01-06 | Cardiac Pacemakers Inc. | Crosslinkable polyisobutylene-based polymers and medical devices containing the same |
US9855415B2 (en) | 2015-07-25 | 2018-01-02 | Cardiac Pacemakers, Inc. | Medical electrical lead with biostable PVDF-based materials |
US9926399B2 (en) | 2012-11-21 | 2018-03-27 | University Of Massachusetts | High strength polyisobutylene polyurethanes |
JP2019508557A (en) * | 2016-05-10 | 2019-03-28 | カーディアック ペースメイカーズ, インコーポレイテッド | Thermosetting polyisobutylene-polyurethane and method for producing the same |
WO2019190910A1 (en) * | 2018-03-26 | 2019-10-03 | Medtronic, Inc. | Modified polyisobutylene-based polymers, methods of making, and medical devices |
WO2019190905A1 (en) * | 2018-03-26 | 2019-10-03 | Medtronic, Inc. | Poly(ether-carbonate)-based polymers and medical devices |
US10465318B2 (en) | 2016-12-27 | 2019-11-05 | Boston Scientific Scimed Inc | Degradable scaffolding for electrospinning |
US10526429B2 (en) | 2017-03-07 | 2020-01-07 | Cardiac Pacemakers, Inc. | Hydroboration/oxidation of allyl-terminated polyisobutylene |
US10835638B2 (en) | 2017-08-17 | 2020-11-17 | Cardiac Pacemakers, Inc. | Photocrosslinked polymers for enhanced durability |
US11155933B2 (en) | 2013-07-22 | 2021-10-26 | Cardiac Pacemakers, Inc. | Lubricious, biocompatible hydrophilic thermoset coating using interpenetrating hydrogel networks |
US11472911B2 (en) | 2018-01-17 | 2022-10-18 | Cardiac Pacemakers, Inc. | End-capped polyisobutylene polyurethane |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7715922B1 (en) * | 2005-11-16 | 2010-05-11 | Pacesetter, Inc. | Polyethylene oxide and polyisobutylene copolymers and their usage on medical devices |
CA2739402A1 (en) * | 2008-10-01 | 2010-04-08 | The University Of Akron | Polymers having both hard and soft segments, and process for making same |
US8674034B2 (en) * | 2009-11-11 | 2014-03-18 | The University Of Akron | Polyisobutylene-based polyurethanes, polyureas and/or polyurethane-polyureas and method for making same |
EP3517145A1 (en) * | 2012-02-08 | 2019-07-31 | Boston Scientific Scimed, Inc. | Surgical scaffolds |
WO2013151656A1 (en) | 2012-04-02 | 2013-10-10 | Medtronic, Inc. | Medical leads |
ES2690824T3 (en) | 2012-07-02 | 2018-11-22 | Boston Scientific Scimed, Inc. | Formation of cardiac valve prosthesis |
CN104640918A (en) * | 2012-07-23 | 2015-05-20 | 阿克伦大学 | Polyisobutylene-based polyurethanes containing organically modified montmorillonite |
CN104602888B (en) * | 2012-09-11 | 2017-09-22 | 心脏起搏器股份公司 | Conformal thin porous layer coating and manufacture method |
US10343385B2 (en) | 2013-07-18 | 2019-07-09 | Boston Scientific Scimed, Inc. | Bodily implant |
WO2015053934A1 (en) | 2013-10-10 | 2015-04-16 | Medtronic, Inc. | Implantable medical devices including a polyether-polyurethane substrate with improved biostability, and methods |
WO2016068934A1 (en) * | 2014-10-30 | 2016-05-06 | Cardiac Pacemakers, Inc. | Solvent free polyisobutylene based polyurethanes |
US10426609B2 (en) | 2015-04-09 | 2019-10-01 | Boston Scientific Scimed, Inc. | Fiber reinforced prosthetic heart valve having undulating fibers |
US10299915B2 (en) | 2015-04-09 | 2019-05-28 | Boston Scientific Scimed, Inc. | Synthetic heart valves composed of zwitterionic polymers |
US10314696B2 (en) | 2015-04-09 | 2019-06-11 | Boston Scientific Scimed, Inc. | Prosthetic heart valves having fiber reinforced leaflets |
WO2016171975A1 (en) | 2015-04-23 | 2016-10-27 | Cardiac Pacemakers, Inc. | Compositions and methods for copolymer solutions with high weight percent copolymers |
US10716671B2 (en) | 2015-07-02 | 2020-07-21 | Boston Scientific Scimed, Inc. | Prosthetic heart valve composed of composite fibers |
US10413403B2 (en) | 2015-07-14 | 2019-09-17 | Boston Scientific Scimed, Inc. | Prosthetic heart valve including self-reinforced composite leaflets |
US10195023B2 (en) | 2015-09-15 | 2019-02-05 | Boston Scientific Scimed, Inc. | Prosthetic heart valves including pre-stressed fibers |
EP3362498A1 (en) * | 2015-10-17 | 2018-08-22 | Cardiac Pacemakers, Inc. | Production of in situ crosslinkable polyisobutylene-polyurethane nanofibers and coatings |
CN109475409B (en) | 2016-05-19 | 2021-02-19 | 波士顿科学国际有限公司 | Prosthetic valves, valve leaflets and related methods |
WO2018200378A1 (en) | 2017-04-25 | 2018-11-01 | Boston Scientific Scimed, Inc. | Biocompatible polyisobutylene-fiber composite materials and methods |
KR102282617B1 (en) * | 2017-05-15 | 2021-07-28 | 다이너파워 컴퍼니 엘엘씨 | Energy storage system for solar energy and solar energy storage method |
US10899869B2 (en) | 2019-01-24 | 2021-01-26 | The University Of Akron | Glycerol containing polyurethanes and polyurethane nanocomposites |
EP4192896A1 (en) * | 2020-08-06 | 2023-06-14 | The University of Akron | Synthesis of high molecular weight and strength polyisobutylene-based polyurethanes and use thereof |
CN112831013B (en) * | 2021-02-25 | 2022-03-29 | 中国科学院长春应用化学研究所 | Functionalized polyurethane and preparation method and application thereof |
Citations (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3328372A (en) * | 1964-05-11 | 1967-06-27 | Exxon Research Engineering Co | Soluble high molecular weight polymers of cyclopentadiene |
US3642964A (en) * | 1969-12-03 | 1972-02-15 | Upjohn Co | Continuous process for the one-shot preparation of a thermoplastic noncellular polyurethane |
US4043331A (en) * | 1974-08-05 | 1977-08-23 | Imperial Chemical Industries Limited | Fibrillar product of electrostatically spun organic material |
US4103079A (en) * | 1975-11-26 | 1978-07-25 | Exxon Research & Engineering Co. | Halogenated organoaluminum compounds and method of preparation |
US4276394A (en) * | 1979-09-10 | 1981-06-30 | The University Of Akron | Novel telechelic polymers, block copolymers and processes for the preparation thereof |
US4316973A (en) * | 1979-09-10 | 1982-02-23 | The University Of Akron | Novel telechelic polymers and processes for the preparation thereof |
US4342849A (en) * | 1979-09-10 | 1982-08-03 | The University Of Akron | Novel telechelic polymers and processes for the preparation thereof |
US4423185A (en) * | 1980-03-03 | 1983-12-27 | Asahi Kasei Kogyo Kabushiki Kaisha | Thermoplastic resinous composition |
US4477604A (en) * | 1982-09-20 | 1984-10-16 | Oechsle Iii Sixtus J | Polyurethane compositions and their use as luting agents |
US4486572A (en) * | 1983-07-06 | 1984-12-04 | University Of Akron | Synthesis of amphiphilic block copolymers and networks |
US4570270A (en) * | 1982-09-20 | 1986-02-18 | Oechsle Iii Sixtus J | Polyurethane compositions and their use as luting agents |
US4675361A (en) * | 1980-02-29 | 1987-06-23 | Thoratec Laboratories Corp. | Polymer systems suitable for blood-contacting surfaces of a biomedical device, and methods for forming |
US4686137A (en) * | 1980-02-29 | 1987-08-11 | Thoratec Laboratories Corp. | Moisture vapor permeable materials |
US4752626A (en) * | 1987-08-27 | 1988-06-21 | General Motors Corporation | Method of making low compression set urethane foams |
US4767885A (en) * | 1984-08-06 | 1988-08-30 | University Of Akron | Sterically hindered binifers telechelic polymers made therefrom |
US4771082A (en) * | 1986-01-30 | 1988-09-13 | Solodovnik Valentin D | Polyurethane foam composition for immobilization in traumatology |
US4861830A (en) * | 1980-02-29 | 1989-08-29 | Th. Goldschmidt Ag | Polymer systems suitable for blood-contacting surfaces of a biomedical device, and methods for forming |
US4880883A (en) * | 1987-06-03 | 1989-11-14 | Wisconsin Alumni Research Foundation | Biocompatible polyurethanes modified with lower alkyl sulfonate and lower alkyl carboxylate |
US4888389A (en) * | 1985-02-05 | 1989-12-19 | University Of Akron | Amphiphilic polymers and method of making said polymers |
US4906673A (en) * | 1987-06-18 | 1990-03-06 | Dai-Ichi Kogyo Seiyaku Co., Ltd. | Polyurethane composition |
US4939184A (en) * | 1989-03-07 | 1990-07-03 | University Of Akron | Polyurethane foam |
US5017664A (en) * | 1987-06-03 | 1991-05-21 | Wisconsin Alumni Research Foundation | Biocompatible polyurethane devices wherein polyurethane is modified with lower alkyl sulfonate and lower alkyl carboxylate |
US5120813A (en) * | 1980-02-29 | 1992-06-09 | Th. Goldschmidt Ag | Moisture vapor permeable materials |
US5149739A (en) * | 1988-08-01 | 1992-09-22 | The Bfgoodrich Company | Fiber-reinforced thermoplastic elastomer polyurethane compositions with either modified and/or unmodified polyolefins |
US5194505A (en) * | 1989-09-29 | 1993-03-16 | E. I. Du Pont De Nemours And Company | Chlorosulfonated polyolefin-modified polyurethane and polyurea compositions and process for making same |
US5212248A (en) * | 1990-08-16 | 1993-05-18 | Basf Aktiengesellschaft | Preparation of hydrocarbons and polymers with allylic chloride end groups friedel-crafts catalyst |
US5340881A (en) * | 1992-11-16 | 1994-08-23 | The University Of Akron | Aldehyde-telechelic polyisobutylenes, catalytic method for preparing the same with high conversion and selectivity, and block copolymers made thereform |
US5428123A (en) * | 1992-04-24 | 1995-06-27 | The Polymer Technology Group | Copolymers and non-porous, semi-permeable membrane thereof and its use for permeating molecules of predetermined molecular weight range |
US5442010A (en) * | 1994-10-04 | 1995-08-15 | Dow Corning Corporation | Epoxy-terminated polyisobutylene-polydimethylsiloxane compositions |
US5589563A (en) * | 1992-04-24 | 1996-12-31 | The Polymer Technology Group | Surface-modifying endgroups for biomedical polymers |
US5637647A (en) * | 1993-10-15 | 1997-06-10 | University Of Massachusetts Lowell | Capping of living polymers |
US5663234A (en) * | 1995-06-15 | 1997-09-02 | The University Of Akron | Cationic multiblock thermoplastic elastomers |
US5741331A (en) * | 1996-07-29 | 1998-04-21 | Corvita Corporation | Biostable elastomeric polymers having quaternary carbons |
US5852118A (en) * | 1996-10-15 | 1998-12-22 | Advanced Elastomer Systems, L.P. | Block copolymers of polyolefins with polyurethanes, copolyesters or copolyamides and their use |
US5874484A (en) * | 1997-01-30 | 1999-02-23 | Shell Oil Company | Use of polyol mixtures in rigid and semi-rigid polyurethane foams |
US6005051A (en) * | 1997-08-06 | 1999-12-21 | The University Of Akron | Multi-component polymeric networks containing polyisobutylene |
US6010715A (en) * | 1992-04-01 | 2000-01-04 | Bertek, Inc. | Transdermal patch incorporating a polymer film incorporated with an active agent |
US6072003A (en) * | 1997-08-25 | 2000-06-06 | Advanced Elastomer Systems, L.P. | Block copolymers of polyolefins with polyurethanes, copolyesters or copolyamides and their use |
US6093197A (en) * | 1997-12-08 | 2000-07-25 | Axon Engineering, Inc. | Spiral nerve cuff electrode implantation tool |
US6200589B1 (en) * | 1996-09-13 | 2001-03-13 | The University Of Akron | Biological implants of semipermeable amphiphilic membranes |
US6228945B1 (en) * | 1999-12-20 | 2001-05-08 | The University Of Akron | Three arm star compositions of matter having diblock arms based on polyisobutylene and methods of preparation |
US6365674B1 (en) * | 1995-03-13 | 2002-04-02 | Bayer Corporation | Thermoplastic polyurethane resin |
US6444334B1 (en) * | 2000-11-10 | 2002-09-03 | Sumitomo Chemical Company, Limited | Polymeric fluorescent substance and polymer light-emitting device using the same |
US6545097B2 (en) * | 2000-12-12 | 2003-04-08 | Scimed Life Systems, Inc. | Drug delivery compositions and medical devices containing block copolymer |
US6555619B1 (en) * | 2000-06-29 | 2003-04-29 | The University Of Akron | Physically crosslinked amphiphilic networks, methods of preparation, and uses thereof |
US20030125499A1 (en) * | 2001-11-14 | 2003-07-03 | Benz Michael Eric | Compounds containing quaternary carbons, medical devices, and methods |
US6600956B2 (en) * | 2001-08-21 | 2003-07-29 | Cyberonics, Inc. | Circumneural electrode assembly |
US6627724B2 (en) * | 1996-09-23 | 2003-09-30 | Aortech Biomaterials Pty Ltd | Polysiloxane-containing polyurethane elastomeric compositions |
US20030204022A1 (en) * | 2002-04-04 | 2003-10-30 | Kennedy Joseph P. | Polyisobutylene-based block anionomers and cationomers and synthesis thereof |
US20040054210A1 (en) * | 2002-09-17 | 2004-03-18 | Medtronic, Inc. | Compounds containing quaternary carbons and silicon-containing groups, medical devices, and methods |
US6849667B2 (en) * | 2000-10-18 | 2005-02-01 | Mitsui Chemicals, Inc. | Foam of thermoplastic urethane elastomer composition and process for producing the foam |
US20050060022A1 (en) * | 2003-05-21 | 2005-03-17 | Felt Jeffrey C. | Polymer stent |
US6870024B2 (en) * | 2002-09-09 | 2005-03-22 | Byk-Chemie Gmbh | Polymeric urea-urethane rheology control agents and a process for their preparation |
US20050288476A1 (en) * | 2004-06-17 | 2005-12-29 | Iskender Yilgor | Thermoplastic copolymers through stoichiometric reactions between diisocyanates and oligomeric diols and diamines |
US20060047083A1 (en) * | 2004-08-30 | 2006-03-02 | Iskender Yilgor | Triblock copolymers and their production methods |
US7105622B2 (en) * | 2004-06-02 | 2006-09-12 | The University Of Akron | Hybrid polyurethanes |
US20060223946A1 (en) * | 2004-02-11 | 2006-10-05 | University Of Massachusetts Lowell | End-capped polymer chains and products thereof |
US20060264577A1 (en) * | 2005-04-08 | 2006-11-23 | Rudolf Faust | Capping reactions in cationic polymerization; kinetic and synthetic utility |
US20070093604A1 (en) * | 2003-07-01 | 2007-04-26 | Joseph Kennedy | Thermoplastic elastomeric multiblock copolymers of isobutylene and norbornene |
US7292890B2 (en) * | 2002-06-20 | 2007-11-06 | Advanced Bionics Corporation | Vagus nerve stimulation via unidirectional propagation of action potentials |
US7347751B2 (en) * | 2004-09-30 | 2008-03-25 | Cardiac Pacemakers, Inc. | Cardiac lead implantation system |
US20080167423A1 (en) * | 2003-05-15 | 2008-07-10 | Stuart Nicholas Richards | Polyurethane Dispersants |
US20100023104A1 (en) * | 2008-06-27 | 2010-01-28 | Cardiac Pacemakers, Inc. | Polyisobutylene urethane, urea and urethane/urea copolymers and medical devices containing the same |
US20100069578A1 (en) * | 2006-11-17 | 2010-03-18 | Rudolf Faust | Functional Hydrocarbon Polymers and Process for Producing Same |
US20100075018A1 (en) * | 2008-09-19 | 2010-03-25 | Shrojalkumar Desai | Surface modification to improve lubricity, abrasion resistance and temperature resilience of leads |
US20100107967A1 (en) * | 2007-03-16 | 2010-05-06 | Ube Industries, Ltd. | Production method of zinc oxide single crystal |
US20100179298A1 (en) * | 2009-01-12 | 2010-07-15 | University Of Massachusetts Lowell | Polyisobutylene-Based Polyurethanes |
US20100241208A1 (en) * | 2009-03-20 | 2010-09-23 | Leonard Pinchuk | Pacemaker Lead and Method of Making Same |
US20110054580A1 (en) * | 2009-09-02 | 2011-03-03 | Shrojalkumar Desai | Polyisobutylene urethane, urea and urethane/urea copolymers and medical leads containing the same |
US20110054581A1 (en) * | 2009-09-02 | 2011-03-03 | Shrojalkumar Desai | Medical devices including polyisobutylene based polymers and derivatives thereof |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL6606553A (en) | 1965-06-18 | 1967-11-13 | ||
US4910321A (en) | 1985-06-20 | 1990-03-20 | University Of Akron | Living catalysts, complexes and polymers therefrom |
BR9003841A (en) | 1990-08-06 | 1992-02-25 | Sika S A | POLYURETHANE RESIN, ADHESIVE, EPOXY RESIN, PROCESS FOR THE PRODUCTION OF THESE RESINS, INK AND USE |
DE4303556C1 (en) | 1993-02-08 | 1994-10-27 | Bayer Ag | Hard polyurethanes or polyurethane foams |
GB9306887D0 (en) | 1993-04-01 | 1993-05-26 | Graham Neil B | Random block copolymers |
DE19610350A1 (en) | 1996-03-15 | 1997-09-18 | Basf Ag | Initiators for the anionically initiated polymerization of monomers having at least one ethylenically unsaturated group |
US5912302A (en) * | 1996-06-11 | 1999-06-15 | Gadkari; Avinash Chandrakant | Elastomeric compositions and a process to produce elastomeric compositions |
BR9806728A (en) | 1997-01-30 | 2000-02-29 | Shell Int Research | Use of mixtures of polyols in rigid and semi-rigid polyurethane foams. |
WO1998033832A1 (en) | 1997-01-30 | 1998-08-06 | Shell Internationale Research Maatschappij B.V. | Use of polyol mixtures in rigid and semi-rigid polyurethane foams |
JP3671624B2 (en) | 1997-10-27 | 2005-07-13 | 株式会社カネカ | Polyurethane elastic fiber |
CN1075103C (en) | 1998-09-21 | 2001-11-21 | 深圳市奥博胶粘剂化工有限公司 | Polyurethane adhesives/sealant composition, precursor and preparation process thereof |
EP1061092A1 (en) | 1999-06-17 | 2000-12-20 | Shell Internationale Researchmaatschappij B.V. | Process for the preparation of a rigid polyurethane foam. |
US7396582B2 (en) * | 2001-04-06 | 2008-07-08 | Advanced Cardiovascular Systems, Inc. | Medical device chemically modified by plasma polymerization |
WO2003042273A1 (en) | 2001-11-14 | 2003-05-22 | Medtronic, Inc. | Compounds containing quaternary carbons, medical devices, and methods |
US20040039437A1 (en) | 2002-08-13 | 2004-02-26 | Medtronic, Inc. | Medical device exhibiting improved adhesion between polymeric coating and substrate |
AU2003298626A1 (en) | 2002-11-12 | 2004-06-03 | The Polymer Technology Group Incorporated | Control of polymer surface molecular architecture via amphipathic endgroups |
US6969744B2 (en) | 2003-06-19 | 2005-11-29 | University Of Southern Mississippi | Living and quasiliving cationic telechelic polymers quenched by N-substituted pyrrole and methods for their preparation |
CA2529420A1 (en) | 2003-06-20 | 2004-12-29 | Rudolf Faust | End-capped polymer chains and products thereof |
JP2006274235A (en) | 2004-07-30 | 2006-10-12 | Fuji Photo Film Co Ltd | Polymerizable composition, optically anisotropic layer, method for producing the same, optical compensatory element, liquid crystal display and liquid crystal projector |
US20070051531A1 (en) | 2005-09-08 | 2007-03-08 | Harshad Borgaonkar | Drug eluting coatings for a medical lead and method therefor |
US7715922B1 (en) * | 2005-11-16 | 2010-05-11 | Pacesetter, Inc. | Polyethylene oxide and polyisobutylene copolymers and their usage on medical devices |
US7553546B1 (en) | 2005-11-16 | 2009-06-30 | Pacesetter, Inc. | Polyethylene oxide and silicone copolymers and their usage on medical devices |
WO2007115198A2 (en) | 2006-03-31 | 2007-10-11 | Advanced Neuromodulation Systems, Inc. | Compliant electrical stimulation leads and methods of fabrication |
EP2004715A2 (en) | 2006-04-07 | 2008-12-24 | University Of Massachusetts Lowell | Method to prepare block copolymers by the combination of cationic and anionic polymerization |
CN101460204B (en) | 2006-05-31 | 2012-10-03 | 株式会社钟化 | Catheter tube and catheter comprising the tube |
EP2474563B1 (en) | 2006-11-30 | 2020-01-08 | The University of Akron | Polyisobutylene-based polyurethane and polyurea |
CA2680321C (en) | 2007-03-09 | 2016-05-03 | The University Of Akron | Bio-artificial pancreas and a procedure for preparation of same |
JP2008238761A (en) | 2007-03-29 | 2008-10-09 | Toyoda Gosei Co Ltd | Polyurethane material and its manufacturing method |
CN103432625B (en) | 2007-04-12 | 2015-12-02 | 阿克伦大学 | Injectible cyanoacrylate-functionalized polyisobutylenes |
CA2691087C (en) | 2007-06-19 | 2016-04-05 | The University Of Akron | Singly-terminated polyisobutylenes and process for making same |
EP2207824A4 (en) | 2007-11-01 | 2011-02-16 | Univ Akron | Thermoplastic amphiphilic co-networks |
CA2739402A1 (en) | 2008-10-01 | 2010-04-08 | The University Of Akron | Polymers having both hard and soft segments, and process for making same |
US20120077934A1 (en) | 2009-03-23 | 2012-03-29 | University Of Massachusetts | Functional Polyisobutylene Based Macromonomers And Methods For Making And Using The Same |
AU2010284137B2 (en) | 2009-08-21 | 2014-11-27 | Cardiac Pacemakers, Inc. | Crosslinkable polyisobutylene-based polymers and medical devices containing the same |
US8674034B2 (en) | 2009-11-11 | 2014-03-18 | The University Of Akron | Polyisobutylene-based polyurethanes, polyureas and/or polyurethane-polyureas and method for making same |
-
2009
- 2009-06-26 EP EP09771131A patent/EP2291204A1/en not_active Withdrawn
- 2009-06-26 WO PCT/US2009/048845 patent/WO2009158609A1/en active Application Filing
- 2009-06-26 JP JP2011516708A patent/JP5592882B2/en active Active
- 2009-06-26 WO PCT/US2009/048827 patent/WO2009158600A1/en active Application Filing
- 2009-06-26 AU AU2009262097A patent/AU2009262097B2/en active Active
- 2009-06-26 US US12/492,483 patent/US8324290B2/en active Active
- 2009-06-26 CN CN2009801332209A patent/CN102131530A/en active Pending
- 2009-06-26 US US12/492,440 patent/US20090326077A1/en not_active Abandoned
-
2012
- 2012-09-14 US US13/618,148 patent/US8501831B2/en active Active
Patent Citations (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3328372A (en) * | 1964-05-11 | 1967-06-27 | Exxon Research Engineering Co | Soluble high molecular weight polymers of cyclopentadiene |
US3642964A (en) * | 1969-12-03 | 1972-02-15 | Upjohn Co | Continuous process for the one-shot preparation of a thermoplastic noncellular polyurethane |
US4043331A (en) * | 1974-08-05 | 1977-08-23 | Imperial Chemical Industries Limited | Fibrillar product of electrostatically spun organic material |
US4103079A (en) * | 1975-11-26 | 1978-07-25 | Exxon Research & Engineering Co. | Halogenated organoaluminum compounds and method of preparation |
US4276394A (en) * | 1979-09-10 | 1981-06-30 | The University Of Akron | Novel telechelic polymers, block copolymers and processes for the preparation thereof |
US4316973A (en) * | 1979-09-10 | 1982-02-23 | The University Of Akron | Novel telechelic polymers and processes for the preparation thereof |
US4342849A (en) * | 1979-09-10 | 1982-08-03 | The University Of Akron | Novel telechelic polymers and processes for the preparation thereof |
US4686137A (en) * | 1980-02-29 | 1987-08-11 | Thoratec Laboratories Corp. | Moisture vapor permeable materials |
US5120813A (en) * | 1980-02-29 | 1992-06-09 | Th. Goldschmidt Ag | Moisture vapor permeable materials |
US4861830A (en) * | 1980-02-29 | 1989-08-29 | Th. Goldschmidt Ag | Polymer systems suitable for blood-contacting surfaces of a biomedical device, and methods for forming |
US4675361A (en) * | 1980-02-29 | 1987-06-23 | Thoratec Laboratories Corp. | Polymer systems suitable for blood-contacting surfaces of a biomedical device, and methods for forming |
US4423185A (en) * | 1980-03-03 | 1983-12-27 | Asahi Kasei Kogyo Kabushiki Kaisha | Thermoplastic resinous composition |
US4570270A (en) * | 1982-09-20 | 1986-02-18 | Oechsle Iii Sixtus J | Polyurethane compositions and their use as luting agents |
US4477604A (en) * | 1982-09-20 | 1984-10-16 | Oechsle Iii Sixtus J | Polyurethane compositions and their use as luting agents |
US4486572A (en) * | 1983-07-06 | 1984-12-04 | University Of Akron | Synthesis of amphiphilic block copolymers and networks |
US4767885A (en) * | 1984-08-06 | 1988-08-30 | University Of Akron | Sterically hindered binifers telechelic polymers made therefrom |
US4888389A (en) * | 1985-02-05 | 1989-12-19 | University Of Akron | Amphiphilic polymers and method of making said polymers |
US4771082A (en) * | 1986-01-30 | 1988-09-13 | Solodovnik Valentin D | Polyurethane foam composition for immobilization in traumatology |
US4880883A (en) * | 1987-06-03 | 1989-11-14 | Wisconsin Alumni Research Foundation | Biocompatible polyurethanes modified with lower alkyl sulfonate and lower alkyl carboxylate |
US5017664A (en) * | 1987-06-03 | 1991-05-21 | Wisconsin Alumni Research Foundation | Biocompatible polyurethane devices wherein polyurethane is modified with lower alkyl sulfonate and lower alkyl carboxylate |
US4906673A (en) * | 1987-06-18 | 1990-03-06 | Dai-Ichi Kogyo Seiyaku Co., Ltd. | Polyurethane composition |
US4752626A (en) * | 1987-08-27 | 1988-06-21 | General Motors Corporation | Method of making low compression set urethane foams |
US5149739A (en) * | 1988-08-01 | 1992-09-22 | The Bfgoodrich Company | Fiber-reinforced thermoplastic elastomer polyurethane compositions with either modified and/or unmodified polyolefins |
US4939184A (en) * | 1989-03-07 | 1990-07-03 | University Of Akron | Polyurethane foam |
US5194505A (en) * | 1989-09-29 | 1993-03-16 | E. I. Du Pont De Nemours And Company | Chlorosulfonated polyolefin-modified polyurethane and polyurea compositions and process for making same |
US5212248A (en) * | 1990-08-16 | 1993-05-18 | Basf Aktiengesellschaft | Preparation of hydrocarbons and polymers with allylic chloride end groups friedel-crafts catalyst |
US5332791A (en) * | 1990-08-16 | 1994-07-26 | Basf Aktiengesellschaft | Polyisobutylene hydrocarbon or polymer containing a double bond allylic to an end amino group |
US6010715A (en) * | 1992-04-01 | 2000-01-04 | Bertek, Inc. | Transdermal patch incorporating a polymer film incorporated with an active agent |
US5428123A (en) * | 1992-04-24 | 1995-06-27 | The Polymer Technology Group | Copolymers and non-porous, semi-permeable membrane thereof and its use for permeating molecules of predetermined molecular weight range |
US5589563A (en) * | 1992-04-24 | 1996-12-31 | The Polymer Technology Group | Surface-modifying endgroups for biomedical polymers |
US5340881A (en) * | 1992-11-16 | 1994-08-23 | The University Of Akron | Aldehyde-telechelic polyisobutylenes, catalytic method for preparing the same with high conversion and selectivity, and block copolymers made thereform |
US5442015A (en) * | 1992-11-16 | 1995-08-15 | The University Of Akron | Aldehyde-telechelic polyisobutylenes, catalytic method for preparing the same with high conversion and selectivity, and block copolymers made therefrom |
US5637647A (en) * | 1993-10-15 | 1997-06-10 | University Of Massachusetts Lowell | Capping of living polymers |
US5677386A (en) * | 1993-10-15 | 1997-10-14 | University Of Massachusetts Lowell | Capping of living polymers |
US5442010A (en) * | 1994-10-04 | 1995-08-15 | Dow Corning Corporation | Epoxy-terminated polyisobutylene-polydimethylsiloxane compositions |
US6365674B1 (en) * | 1995-03-13 | 2002-04-02 | Bayer Corporation | Thermoplastic polyurethane resin |
US5663234A (en) * | 1995-06-15 | 1997-09-02 | The University Of Akron | Cationic multiblock thermoplastic elastomers |
US5741331A (en) * | 1996-07-29 | 1998-04-21 | Corvita Corporation | Biostable elastomeric polymers having quaternary carbons |
US6200589B1 (en) * | 1996-09-13 | 2001-03-13 | The University Of Akron | Biological implants of semipermeable amphiphilic membranes |
US6627724B2 (en) * | 1996-09-23 | 2003-09-30 | Aortech Biomaterials Pty Ltd | Polysiloxane-containing polyurethane elastomeric compositions |
US5852118A (en) * | 1996-10-15 | 1998-12-22 | Advanced Elastomer Systems, L.P. | Block copolymers of polyolefins with polyurethanes, copolyesters or copolyamides and their use |
US5874484A (en) * | 1997-01-30 | 1999-02-23 | Shell Oil Company | Use of polyol mixtures in rigid and semi-rigid polyurethane foams |
US6005051A (en) * | 1997-08-06 | 1999-12-21 | The University Of Akron | Multi-component polymeric networks containing polyisobutylene |
US6072003A (en) * | 1997-08-25 | 2000-06-06 | Advanced Elastomer Systems, L.P. | Block copolymers of polyolefins with polyurethanes, copolyesters or copolyamides and their use |
US6093197A (en) * | 1997-12-08 | 2000-07-25 | Axon Engineering, Inc. | Spiral nerve cuff electrode implantation tool |
US6228945B1 (en) * | 1999-12-20 | 2001-05-08 | The University Of Akron | Three arm star compositions of matter having diblock arms based on polyisobutylene and methods of preparation |
US6555619B1 (en) * | 2000-06-29 | 2003-04-29 | The University Of Akron | Physically crosslinked amphiphilic networks, methods of preparation, and uses thereof |
US6849667B2 (en) * | 2000-10-18 | 2005-02-01 | Mitsui Chemicals, Inc. | Foam of thermoplastic urethane elastomer composition and process for producing the foam |
US6444334B1 (en) * | 2000-11-10 | 2002-09-03 | Sumitomo Chemical Company, Limited | Polymeric fluorescent substance and polymer light-emitting device using the same |
US6545097B2 (en) * | 2000-12-12 | 2003-04-08 | Scimed Life Systems, Inc. | Drug delivery compositions and medical devices containing block copolymer |
US6600956B2 (en) * | 2001-08-21 | 2003-07-29 | Cyberonics, Inc. | Circumneural electrode assembly |
US7101956B2 (en) * | 2001-11-14 | 2006-09-05 | Medtronic, Inc. | Compounds containing quaternary carbons, medical devices, and methods |
US20030125499A1 (en) * | 2001-11-14 | 2003-07-03 | Benz Michael Eric | Compounds containing quaternary carbons, medical devices, and methods |
US20070203302A1 (en) * | 2002-04-04 | 2007-08-30 | Kennedy Joseph P | Polyisobutylene-based block anionomers and cationomers and synthesis thereof |
US7196142B2 (en) * | 2002-04-04 | 2007-03-27 | The University Of Akron | Polyisobutylene-based block anionomers and cationomers and synthesis thereof |
US20030204022A1 (en) * | 2002-04-04 | 2003-10-30 | Kennedy Joseph P. | Polyisobutylene-based block anionomers and cationomers and synthesis thereof |
US7292890B2 (en) * | 2002-06-20 | 2007-11-06 | Advanced Bionics Corporation | Vagus nerve stimulation via unidirectional propagation of action potentials |
US6870024B2 (en) * | 2002-09-09 | 2005-03-22 | Byk-Chemie Gmbh | Polymeric urea-urethane rheology control agents and a process for their preparation |
US20040054210A1 (en) * | 2002-09-17 | 2004-03-18 | Medtronic, Inc. | Compounds containing quaternary carbons and silicon-containing groups, medical devices, and methods |
US20080167423A1 (en) * | 2003-05-15 | 2008-07-10 | Stuart Nicholas Richards | Polyurethane Dispersants |
US20050060022A1 (en) * | 2003-05-21 | 2005-03-17 | Felt Jeffrey C. | Polymer stent |
US20070093604A1 (en) * | 2003-07-01 | 2007-04-26 | Joseph Kennedy | Thermoplastic elastomeric multiblock copolymers of isobutylene and norbornene |
US20060223946A1 (en) * | 2004-02-11 | 2006-10-05 | University Of Massachusetts Lowell | End-capped polymer chains and products thereof |
US7105622B2 (en) * | 2004-06-02 | 2006-09-12 | The University Of Akron | Hybrid polyurethanes |
US20050288476A1 (en) * | 2004-06-17 | 2005-12-29 | Iskender Yilgor | Thermoplastic copolymers through stoichiometric reactions between diisocyanates and oligomeric diols and diamines |
US20060047083A1 (en) * | 2004-08-30 | 2006-03-02 | Iskender Yilgor | Triblock copolymers and their production methods |
US7347751B2 (en) * | 2004-09-30 | 2008-03-25 | Cardiac Pacemakers, Inc. | Cardiac lead implantation system |
US20060264577A1 (en) * | 2005-04-08 | 2006-11-23 | Rudolf Faust | Capping reactions in cationic polymerization; kinetic and synthetic utility |
US20100069578A1 (en) * | 2006-11-17 | 2010-03-18 | Rudolf Faust | Functional Hydrocarbon Polymers and Process for Producing Same |
US20100107967A1 (en) * | 2007-03-16 | 2010-05-06 | Ube Industries, Ltd. | Production method of zinc oxide single crystal |
US20100023104A1 (en) * | 2008-06-27 | 2010-01-28 | Cardiac Pacemakers, Inc. | Polyisobutylene urethane, urea and urethane/urea copolymers and medical devices containing the same |
US20100075018A1 (en) * | 2008-09-19 | 2010-03-25 | Shrojalkumar Desai | Surface modification to improve lubricity, abrasion resistance and temperature resilience of leads |
US20100179298A1 (en) * | 2009-01-12 | 2010-07-15 | University Of Massachusetts Lowell | Polyisobutylene-Based Polyurethanes |
US20100241208A1 (en) * | 2009-03-20 | 2010-09-23 | Leonard Pinchuk | Pacemaker Lead and Method of Making Same |
US20110054580A1 (en) * | 2009-09-02 | 2011-03-03 | Shrojalkumar Desai | Polyisobutylene urethane, urea and urethane/urea copolymers and medical leads containing the same |
US20110054581A1 (en) * | 2009-09-02 | 2011-03-03 | Shrojalkumar Desai | Medical devices including polyisobutylene based polymers and derivatives thereof |
Cited By (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090187162A1 (en) * | 2006-05-31 | 2009-07-23 | Kaneka Corporation | Catheter Tube and Catheter Comprising the Tube |
US7998124B2 (en) * | 2006-05-31 | 2011-08-16 | Kaneka Corporation | Catheter tube and catheter comprising the tube |
US8324290B2 (en) | 2008-06-27 | 2012-12-04 | Cardiac Pacemakers, Inc. | Polyisobutylene urethane, urea and urethane/urea copolymers and medical devices containing the same |
US20100023104A1 (en) * | 2008-06-27 | 2010-01-28 | Cardiac Pacemakers, Inc. | Polyisobutylene urethane, urea and urethane/urea copolymers and medical devices containing the same |
US8501831B2 (en) | 2008-06-27 | 2013-08-06 | Cardiac Pacemakers, Inc. | Polyisobutylene urethane, urea and urethane/urea copolymers and medical devices containing the same |
US20100166820A1 (en) * | 2008-12-31 | 2010-07-01 | Boston Scientific Scimed, Inc. | Copolymers having polyisobutylene and biodegradable polymer segments |
US9631042B2 (en) | 2008-12-31 | 2017-04-25 | Boston Scientific Scimed, Inc. | Copolymers having polyisobutylene and biodegradable polymer segments |
US8911760B2 (en) | 2008-12-31 | 2014-12-16 | Boston Scientific Scimed, Inc. | Copolymers having polyisobutylene and biodegradable polymer segments |
US11174336B2 (en) | 2009-01-12 | 2021-11-16 | University Of Massachusetts Lowell | Polyisobutylene-based polyurethanes |
US9574043B2 (en) | 2009-01-12 | 2017-02-21 | University Of Massachusetts Lowell | Polyisobutylene-based polyurethanes |
US20100179298A1 (en) * | 2009-01-12 | 2010-07-15 | University Of Massachusetts Lowell | Polyisobutylene-Based Polyurethanes |
US10513576B2 (en) | 2009-01-12 | 2019-12-24 | University of Masschusetts Lowell | Polyisobutylene-based polyurethanes |
US8962785B2 (en) | 2009-01-12 | 2015-02-24 | University Of Massachusetts Lowell | Polyisobutylene-based polyurethanes |
US8927660B2 (en) | 2009-08-21 | 2015-01-06 | Cardiac Pacemakers Inc. | Crosslinkable polyisobutylene-based polymers and medical devices containing the same |
US8676344B2 (en) | 2009-09-02 | 2014-03-18 | Cardiac Pacemakers Inc. | Polyisobutylene urethane, urea and urethane/urea copolymers and medical leads containing the same |
US8903507B2 (en) | 2009-09-02 | 2014-12-02 | Cardiac Pacemakers, Inc. | Polyisobutylene urethane, urea and urethane/urea copolymers and medical leads containing the same |
US20110054581A1 (en) * | 2009-09-02 | 2011-03-03 | Shrojalkumar Desai | Medical devices including polyisobutylene based polymers and derivatives thereof |
US8374704B2 (en) | 2009-09-02 | 2013-02-12 | Cardiac Pacemakers, Inc. | Polyisobutylene urethane, urea and urethane/urea copolymers and medical leads containing the same |
US8942823B2 (en) | 2009-09-02 | 2015-01-27 | Cardiac Pacemakers, Inc. | Medical devices including polyisobutylene based polymers and derivatives thereof |
US8644952B2 (en) | 2009-09-02 | 2014-02-04 | Cardiac Pacemakers, Inc. | Medical devices including polyisobutylene based polymers and derivatives thereof |
US20110054580A1 (en) * | 2009-09-02 | 2011-03-03 | Shrojalkumar Desai | Polyisobutylene urethane, urea and urethane/urea copolymers and medical leads containing the same |
US20110152989A1 (en) * | 2009-12-23 | 2011-06-23 | Pacesetter, Inc. | Soft abrasion-resistant polyisobutylene urethane copolymers |
US8660663B2 (en) | 2010-12-20 | 2014-02-25 | Cardiac Pacemakers, Inc. | Lead having a conductive polymer conductor |
US20130041108A1 (en) * | 2011-05-19 | 2013-02-14 | Joseph P. Kennedy | Polymers having both hard and soft segments, and process for making same |
US8965531B2 (en) | 2011-08-12 | 2015-02-24 | Cardiac Pacemakers, Inc. | Method for coating devices using electrospinning and melt blowing |
US9132269B2 (en) | 2011-08-12 | 2015-09-15 | Cardiac Pacemakers, Inc. | Method for coating devices using electrospinning |
US9415206B2 (en) | 2011-08-12 | 2016-08-16 | Cardiac Pacemakers, Inc. | Method for coating devices using electrospinning |
US8903506B2 (en) | 2011-08-12 | 2014-12-02 | Cardiac Pacemakers | Method for coating devices using electrospinning and melt blowing |
US9926399B2 (en) | 2012-11-21 | 2018-03-27 | University Of Massachusetts | High strength polyisobutylene polyurethanes |
US10562998B2 (en) | 2012-11-21 | 2020-02-18 | University Of Massachusetts | High strength polyisobutylene polyurethanes |
US11155933B2 (en) | 2013-07-22 | 2021-10-26 | Cardiac Pacemakers, Inc. | Lubricious, biocompatible hydrophilic thermoset coating using interpenetrating hydrogel networks |
US9855415B2 (en) | 2015-07-25 | 2018-01-02 | Cardiac Pacemakers, Inc. | Medical electrical lead with biostable PVDF-based materials |
JP2019508557A (en) * | 2016-05-10 | 2019-03-28 | カーディアック ペースメイカーズ, インコーポレイテッド | Thermosetting polyisobutylene-polyurethane and method for producing the same |
US10465318B2 (en) | 2016-12-27 | 2019-11-05 | Boston Scientific Scimed Inc | Degradable scaffolding for electrospinning |
US10526429B2 (en) | 2017-03-07 | 2020-01-07 | Cardiac Pacemakers, Inc. | Hydroboration/oxidation of allyl-terminated polyisobutylene |
US10835638B2 (en) | 2017-08-17 | 2020-11-17 | Cardiac Pacemakers, Inc. | Photocrosslinked polymers for enhanced durability |
US11472911B2 (en) | 2018-01-17 | 2022-10-18 | Cardiac Pacemakers, Inc. | End-capped polyisobutylene polyurethane |
US11851522B2 (en) | 2018-01-17 | 2023-12-26 | Cardiac Pacemakers, Inc. | End-capped polyisobutylene polyurethane |
CN111902448A (en) * | 2018-03-26 | 2020-11-06 | 美敦力公司 | Poly (ether-carbonate) -based polymer and medical device |
US10882945B2 (en) | 2018-03-26 | 2021-01-05 | Medtronic, Inc. | Modified polyisobutylene-based polymers, methods of making, and medical devices |
WO2019190905A1 (en) * | 2018-03-26 | 2019-10-03 | Medtronic, Inc. | Poly(ether-carbonate)-based polymers and medical devices |
WO2019190910A1 (en) * | 2018-03-26 | 2019-10-03 | Medtronic, Inc. | Modified polyisobutylene-based polymers, methods of making, and medical devices |
US11548974B2 (en) | 2018-03-26 | 2023-01-10 | Medtronic, Inc. | Modified polyisobutylene-based polymers, methods of making, and medical devices |
Also Published As
Publication number | Publication date |
---|---|
JP2011526326A (en) | 2011-10-06 |
US20130013040A1 (en) | 2013-01-10 |
EP2291204A1 (en) | 2011-03-09 |
AU2009262097B2 (en) | 2014-03-20 |
US8501831B2 (en) | 2013-08-06 |
US8324290B2 (en) | 2012-12-04 |
JP5592882B2 (en) | 2014-09-17 |
US20100023104A1 (en) | 2010-01-28 |
WO2009158600A1 (en) | 2009-12-30 |
AU2009262097A1 (en) | 2009-12-30 |
CN102131530A (en) | 2011-07-20 |
WO2009158609A1 (en) | 2009-12-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8324290B2 (en) | Polyisobutylene urethane, urea and urethane/urea copolymers and medical devices containing the same | |
US8927660B2 (en) | Crosslinkable polyisobutylene-based polymers and medical devices containing the same | |
US9631042B2 (en) | Copolymers having polyisobutylene and biodegradable polymer segments | |
US8187623B2 (en) | Medical copolymers | |
EP2237810B1 (en) | Biodegradable polymers | |
EP2007447A2 (en) | Medical devices having biodegradable polymeric regions | |
US8202654B2 (en) | Medical devices having fluorocarbon polymer coatings | |
WO2011019952A1 (en) | Polymers having lipophilic hydrocarbon and biodegradable polymeric segments |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: CARIDAC PACEMARKERS, INC., MINNESOTA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DESAI, SHROJALKUMAR;SCHWARZ, MARLENE C.;BODEN, MARK;AND OTHERS;REEL/FRAME:023235/0647;SIGNING DATES FROM 20090702 TO 20090727 |
|
AS | Assignment |
Owner name: CARDIAC PACEMAKERS, INC., MINNESOTA Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE PREVIOUSLY RECORDED ON REEL 023235 FRAME 0647;ASSIGNORS:DESAI, SHROJALKUMAR;SCHWARZ, MARLENE C.;BODEN, MARK;AND OTHERS;REEL/FRAME:023265/0624;SIGNING DATES FROM 20090702 TO 20090727 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |